@article{2011,
    volume = {47},
    month = {sep},
    year = {2011},
    doi = {10.1016/s0959-8049(11)70397-5},
    pages = {S43},
    publisher = {Elsevier {BV}},
    title = {182 {INVITED} Paedatrics as Model of Centralising Treatment of Rare Cancers},
    journal = {European Journal of Cancer},
}

@article{Abdelshafy2018,
    journal = {Annals of Oncology},
    month = {oct},
    volume = {29},
    author = {M. Abdelshafy and Y. El Dakdouki and L. Verlingue and A. Hollebecque and L. Lacroix and S. Postel-Vinay and A. Varga and R. Balheda and J.-M. Michot and A. Marabelle and E. Rouleau and E. Solary and T. de Baere and E. Angevin and V. Ribrag and S. Michiels and F. Andr{\'{e}} and J.-Y. Scoazec and J.-C. Soria and C. Massard},
    title = {Precision medicine for patients with rare cancers: An effective strategy within the prospective {MOSCATO} trial},
    pages = {viii667},
    year = {2018},
    doi = {10.1093/annonc/mdy303.055},
    publisher = {Elsevier {BV}},
}

@article{Abel2015,
    author = {G A Abel and J Shelton and S Johnson and L Elliss-Brookes and G Lyratzopoulos},
    journal = {British Journal of Cancer},
    title = {Cancer-specific variation in emergency presentation by sex, age and deprivation across 27 common and rarer cancers},
    volume = {112},
    month = {mar},
    number = {S1},
    doi = {10.1038/bjc.2015.52},
    publisher = {Springer Science and Business Media {LLC}},
    pages = {S129--S136},
    year = {2015},
}

@article{Acharya2005,
    year = {2005},
    month = {dec},
    author = {Sheetal Acharya and Martee L Hensley and Anthony C Montag and Gini F Fleming},
    number = {12},
    volume = {6},
    doi = {10.1016/s1470-2045(05)70463-0},
    pages = {961--971},
    title = {Rare uterine cancers},
    journal = {The Lancet Oncology},
    publisher = {Elsevier {BV}},
}

@article{Aggarwal2011,
    month = {nov},
    doi = {10.1016/j.jval.2011.08.1125},
    year = {2011},
    volume = {14},
    pages = {A438},
    number = {7},
    author = {S. Aggarwal},
    title = {{PCN}24 Budget Impact Model for Rare Cancer Treatment: Case in Point Cutaneous T-Cell Lymphoma},
    journal = {Value in Health},
    publisher = {Elsevier {BV}},
}

@article{Amaya2019,
    publisher = {Elsevier {BV}},
    pages = {vi137},
    doi = {10.1093/annonc/mdz343.088},
    title = {{ROCK} Trial ({NCCH}1709): Nivolumab monotherapy in Rare cancer patients with mismatch repair deficiency biomarker: phase {II}},
    month = {oct},
    author = {Yosuke Amaya and Kan Yonemori and Hitomi Sumiyoshi Okuma and Shoko Narita and Akihiro Hirakawa and Natsuko Okita and Tamie Sukigara and Masashi Kanai and Manabu Muto and Kenichi Nakamura and Yasuhiro Fujiwara},
    volume = {30},
    year = {2019},
    journal = {Annals of Oncology},
}

@article{Andrews2016,
    year = {2016},
    pages = {751--753},
    month = {nov},
    title = {Challenges in studying very rare cancer outcomes and infrequent exposures: example of teriparatide and osteosarcoma},
    volume = {26},
    number = {11},
    doi = {10.1016/j.annepidem.2016.08.011},
    publisher = {Elsevier {BV}},
    journal = {Annals of Epidemiology},
    author = {Elizabeth B. Andrews and Alicia Gilsenan and Kirk Midkiff and David Harris},
}

@article{Angeli2022,
    doi = {10.1016/j.jbi.2021.103957},
    year = {2022},
    title = {Class imbalance in out-of-distribution datasets: Improving the robustness of the {TextCNN} for the classification of rare cancer types},
    month = {jan},
    publisher = {Elsevier {BV}},
    author = {Kevin De Angeli and Shang Gao and Ioana Danciu and Eric B. Durbin and Xiao-Cheng Wu and Antoinette Stroup and Jennifer Doherty and Stephen Schwartz and Charles Wiggins and Mark Damesyn and Linda Coyle and Lynne Penberthy and Georgia D. Tourassi and Hong-Jun Yoon},
    volume = {125},
    journal = {Journal of Biomedical Informatics},
    pages = {103957},
}

@article{Ashley2015,
    month = {apr},
    author = {David Ashley and David Thomas and Lia Gore and Rob Carter and John R Zalcberg and Ren{\'{e}}e Otmar and Julian Savulescu},
    volume = {16},
    publisher = {Elsevier {BV}},
    number = {4},
    pages = {e190--e194},
    title = {Accepting risk in the acceleration of drug development for rare cancers},
    year = {2015},
    doi = {10.1016/s1470-2045(14)71153-2},
    journal = {The Lancet Oncology},
}

@article{Atalar2018,
    publisher = {Elsevier {BV}},
    volume = {127},
    number = {1},
    pages = {96--102},
    month = {apr},
    year = {2018},
    author = {Banu Atalar and Mahmut Ozsahin and Jason Call and Aleksandra Napieralska and Serra Kamer and Salvador Villa and Petek Erpolat and Laura Negretti and Yasmin Lassen-Ramshad and Cem Onal and Serap Akyurek and Gamze Ugurluer and Brigitta G. Baumert and Stephanie Servagi-Vernat and Robert C. Miller and Enis Ozyar and Terence T. Sio},
    doi = {10.1016/j.radonc.2017.12.028},
    journal = {Radiotherapy and Oncology},
    title = {Treatment outcome and prognostic factors for adult patients with medulloblastoma: The Rare Cancer Network ({RCN}) experience},
}

@article{balcerska2004rare,
    year = {2004},
    journal = {Przeglad lekarski},
    url = {https://ruj.uj.edu.pl/xmlui/bitstream/handle/item/272875/klekawka_balwierz_et-al_nowotwory_rzadkie_czy_rzeczywiscie_rzadkie_w_populacji_polskich_dzieci_2004.pdf?sequence=1&isAllowed=y},
    pages = {57--61},
    title = {Rare tumours--are they really rare in the Polish children population?},
    volume = {61},
    author = {Balcerska, Anna and Godzi{\'n}ski, Jan and Bie{\'n}, Ewa and Stachowicz-Stencel, Teresa and Sulka, Wojciech and Rapa{\l}a, Ma{\l}gorzata and Izycka-Swieszewska, Ewa and Perek-Polnik, Marta and Drogosiewicz, Monika and Perek, Danuta and others},
}

@article{Balmant2019,
    publisher = {Wiley},
    journal = {Cancer},
    year = {2019},
    month = {apr},
    title = {Rare cancers in childhood and adolescence in Brazil: First report of data from 19 population-based cancer registries},
    author = {Nathalie V. Balmant and Rejane de Souza Reis and Marceli de Oliveira Santos and Beatriz de Camargo and Gemma Gatta},
    doi = {10.1002/cncr.32121},
}

@article{barrenho_inequities_2022,
    author = {Barrenho, Eliana and Halmai, Réka and Miraldo, Marisa and Tzintzun, Iván and Raïs Ali, Setti and Toulemon, Léa and Dupont, Jean-Claude K. and Rochaix, Lise},
    date = {2022-06},
    volume = {302},
    urldate = {2022-05-17},
    langid = {english},
    url = {https://linkinghub.elsevier.com/retrieve/pii/S0277953622002593},
    year = {2022},
    journal = {Social Science and Medicine},
    doi = {10.1016/j.socscimed.2022.114953},
    publisher = {Elsevier {BV}},
    journaltitle = {Social Science \& Medicine},
    qualityassured = {qualityAssured},
    pages = {114953},
    issn = {02779536},
    title = {Inequities in cancer drug development in terms of unmet medical need},
    month = {jun},
    shortjournal = {Social Science and Medicine},
}

@article{Bell2019,
    doi = {10.1186/s13643-019-1017-5},
    month = {apr},
    volume = {8},
    title = {Communication strategies for rare cancers: a systematic review protocol},
    publisher = {Springer Science and Business Media {LLC}},
    year = {2019},
    journal = {Systematic Reviews},
    number = {1},
    author = {Catherine Bell and Katie Kerr and Kerry Moore and Charlene McShane and Lesley Anderson and Amy Jayne McKnight and Helen McAneney},
}

@article{Bergerot2018,
    doi = {10.1002/pon.4873},
    journal = {Psycho-Oncology},
    year = {2018},
    readstatus = {read},
    volume = {27},
    title = {Assessment of distress and quality of life in rare cancers},
    month = {sep},
    author = {Cristiane Decat Bergerot and Paulo Gustavo Bergerot and Errol J. Philip and Edvane Birelo Lopes De Domenico and Maria Fernanda Marcusso Manhaes and Renata Nunes Pedras and Meghan M. Salgia and Nazli Dizman and Kimlin Tam Ashing and Min Li and William Dale and Sumanta K. Pal},
    pages = {2740--2746},
    number = {12},
    publisher = {Wiley},
}

@article{berrino2009comparative,
    publisher = {Elsevier},
    number = {6},
    volume = {45},
    year = {2009},
    author = {Berrino, Franco and Verdecchia, Arduino and Lutz, Jean Michel and Lombardo, Claudio and Micheli, Andrea and Capocaccia, Riccardo},
    journal = {European Journal of Cancer},
    pages = {901--908},
    url = {https://www.nicer.org/assets/files/p_Comparative_cancer_survival_information_in_Europe.pdf},
    title = {Comparative cancer survival information in Europe},
}

@article{Bien2011,
    number = {15},
    volume = {47},
    title = {Pancreatoblastoma: A report from the European cooperative study group for paediatric rare tumours ({EXPeRT})},
    month = {oct},
    author = {Ewa Bien and Jan Godzinski and Patrizia Dall'Igna and Anne-Sophie Defachelles and Teresa Stachowicz-Stencel and Daniel Orbach and Gianni Bisogno and Giovanni Cecchetto and Steven Warmann and Verena Ellerkamp and Bernadette Brennan and Anna Balcerska and Malgorzata Rapala and Ines Brecht and Dominik Schneider and Andrea Ferrari},
    journal = {European Journal of Cancer},
    doi = {10.1016/j.ejca.2011.05.022},
    publisher = {Elsevier {BV}},
    year = {2011},
    pages = {2347--2352},
}

@article{bilkey_descriptive_2021,
    journaltitle = {{BMC} Cancer},
    pages = {779},
    title = {Descriptive epidemiological study of rare, less common and common cancers in Western Australia},
    author = {Bilkey, Gemma A. and Trevithick, Richard W. and Coles, Emily P. and Girschik, Jennifer and Nowak, Kristen J.},
    abstract = {Abstract

Background
There are no epidemiological studies describing rare cancers in Western Australia ({WA}). We aimed to fill this gap by estimating the incidence and five-year survival of rare, less common and common cancers in {WA}, based on definitions for rarity used by the Australian Institute of Health and Welfare and cancer groupings from the project on Surveillance of Rare Cancers in Europe ({RARECARE}). This research will enable policy- and decision-makers to better understand the size and nature of the public health problem presented by rare cancers in {WA}. It is anticipated that this study will inform improved health service design and delivery for all {WA} cancer patients, but particularly those with rare and less common cancers.


Methods
We estimated incidence and five-year survival rates of rare, less common and common cancers in {WA} using data sourced from the {WA} Cancer Registry for the 2013–2017 period. Cancers were defined as rare ({\textless} 6), less common (6–12), or common ({\textgreater} 12) based on their crude incidence rate per 100,000 people per year.


Results
Rare cancers make up 21.5\% of all cancer diagnoses in {WA}, with a significantly poorer five-year survival of 58.2\% (95\% confidence interval ({CI}) 57.3–59.1\%), compared to patients diagnosed with a common cancer, whose five-year survival was 87.8\% (95\% {CI} 87.3–88.3\%). Survival for less common cancers was significantly poorer than both rare and common cancers, at 48.1\% (95\% {CI} 47.3–49.0\%). Together, rare and less common cancers represent 48.4\% of all cancer diagnoses in {WA}.


Conclusions
While rare cancers are individually scarce, collectively over one in five cancer patients in {WA} are diagnosed with a rare cancer. These patients experience significantly worse prognoses compared to patients with common cancers.},
    file = {Full Text:C\:\\Users\\Kostadin\\Zotero\\storage\\Y44JGW4I\\Bilkey и др. - 2021 - Descriptive epidemiological study of rare, less co.pdf:application/pdf},
    langid = {english},
    issn = {1471-2407},
    date = {2021-12},
    number = {1},
    shortjournal = {{BMC} Cancer},
    doi = {10.1186/s12885-021-08501-4},
    urldate = {2022-05-17},
    readstatus = {read},
    qualityassured = {qualityAssured},
    url = {https://bmccancer.biomedcentral.com/articles/10.1186/s12885-021-08501-4},
    volume = {21},
}

@article{Billingham2016,
    title = {Research methods to change clinical practice for patients with rare cancers},
    author = {Lucinda Billingham and Kinga Malottki and Neil Steven},
    pages = {e70--e80},
    volume = {17},
    relevance = {relevant},
    doi = {10.1016/s1470-2045(15)00396-4},
    publisher = {Elsevier {BV}},
    number = {2},
    journal = {The Lancet Oncology},
    month = {feb},
    year = {2016},
}

@article{Bisogno2012,
    number = {06},
    pages = {416--420},
    month = {nov},
    doi = {10.1055/s-0032-1327608},
    year = {2012},
    journal = {Klinische Pädiatrie},
    author = {G. Bisogno and A. Ferrari and E. Bien and I. Brecht and B. Brennan and G. Cecchetto and J. Godzinski and D. Orbach and Y. Reguerre and T. Stachowicz-Stencel and D. Schneider},
    volume = {224},
    title = {Rare Cancers in Children {\textendash} The {EXPeRT} Initiative: A Report from the European Cooperative Study Group on Pediatric Rare Tumors},
    publisher = {Georg Thieme Verlag {KG}},
}

@article{Bisoqno2011,
    year = {2011},
    pages = {S27},
    publisher = {Elsevier {BV}},
    author = {G. Bisoqno},
    doi = {10.1016/s0959-8049(11)70320-3},
    journal = {European Journal of Cancer},
    readstatus = {read},
    month = {sep},
    title = {105 {INVITED} Very Rare Cancers in Children {\textendash} From {TREP} to {EXPeRT}},
    volume = {47},
}

@article{Blay2021,
    doi = {10.1016/j.esmoop.2021.100174},
    month = {aug},
    number = {4},
    volume = {6},
    pages = {100174},
    publisher = {Elsevier {BV}},
    year = {2021},
    title = {European Reference Network for rare adult solid cancers, statement and integration to health care systems of member states: a position paper of the {ERN} {EURACAN}},
    journal = {{ESMO} Open},
    author = {J.-Y. Blay and P. Casali and C. Bouvier and C. Dehais and I. Galloway and J. Gietema and J. Hal{\'{a}}mkov{\'{a}} and N. Hindi and A. Idbaih and E. Kinloch and H.-J. Klümpen and T. Kolarova and K. Kopeckova and J. Lovey and M. Magalhaes and K. Oselin and S. Piperno-Neumann and A. Ravnsbaek and M. Rogasik and A. Safwat and S. Scheipl and M. Seckl and J. Taylor and M. Temnyk and A. Trama and M. Urbonas and M. Wartenberg and A. Weinman},
}

@article{Blay2021a,
    month = {feb},
    journal = {The Lancet},
    doi = {10.1016/s0140-6736(21)00264-6},
    publisher = {Elsevier {BV}},
    number = {10276},
    volume = {397},
    pages = {793},
    author = {Jean-Yves Blay and Pierre Fenaux and Ruth Ladenstein and Nicoline Hoogerbrugge},
    year = {2021},
    title = {Continue rare cancers collaboration with European Reference Networks after Brexit},
}

@article{blay_value_2016,
    title = {The value of research collaborations and consortia in rare cancers},
    url = {https://linkinghub.elsevier.com/retrieve/pii/S1470204515003885},
    volume = {17},
    langid = {english},
    author = {Blay, Jean-Yves and Coindre, Jean-Michel and Ducimetière, Françoise and Ray-Coquard, Isabelle},
    doi = {10.1016/S1470-2045(15)00388-5},
    pages = {e62--e69},
    qualityassured = {qualityAssured},
    shortjournal = {The Lancet Oncology},
    urldate = {2022-05-17},
    date = {2016-02},
    number = {2},
    journaltitle = {The Lancet Oncology},
    issn = {14702045},
}

@article{Bogaerts2015,
    publisher = {Elsevier {BV}},
    author = {Bogaerts, Jan and Sydes, Matthew R. and Keat, Nicola and {McConnell}, Andrea and Benson, Al and Ho, Alan and Roth, Arnaud and Fortpied, Catherine and Eng, Cathy and Peckitt, Clare and Coens, Corneel and Pettaway, Curtis and Arnold, Dirk and Hall, Emma and Marshall, Ernie and Sclafani, Francesco and Hatcher, Helen and Earl, Helena and Ray-Coquard, Isabelle and Paul, James and Blay, Jean-Yves and Whelan, Jeremy and Panageas, Kathy and Wheatley, Keith and Harrington, Kevin and Licitra, Lisa and Billingham, Lucinda and Hensley, Martee and {McCabe}, Martin and Patel, Poulam M. and Carvajal, Richard and Wilson, Richard and Glynne-Jones, Rob and {McWilliams}, Rob and Leyvraz, Serge and Rao, Sheela and Nicholson, Steve and Filiaci, Virginia and Negrouk, Anastassia and Lacombe, Denis and Dupont, Elisabeth and Pauporté, Iris and Welch, John J. and Law, Kate and Trimble, Ted and Seymour, Matthew},
    urldate = {2022-05-17},
    shorttitle = {Clinical trial designs for rare diseases},
    journal = {European Journal of Cancer},
    volume = {51},
    pages = {271--281},
    doi = {10.1016/j.ejca.2014.10.027},
    shortjournal = {European Journal of Cancer},
    issn = {09598049},
    month = {feb},
    number = {3},
    date = {2015-02},
    file = {Full Text:C\:\\Users\\Kostadin\\Zotero\\storage\\LQPH7D5S\\Bogaerts и др. - 2015 - Clinical trial designs for rare diseases Studies .pdf:application/pdf},
    qualityassured = {qualityAssured},
    langid = {english},
    title = {Clinical trial designs for rare diseases: Studies developed and discussed by the International Rare Cancers Initiative},
    url = {https://linkinghub.elsevier.com/retrieve/pii/S0959804914010636},
    year = {2015},
    journaltitle = {European Journal of Cancer},
}

@article{Botta2020,
    title = {Incidence and survival of rare cancers in the {US} and Europe},
    month = {may},
    author = {Laura Botta and Gemma Gatta and Annalisa Trama and Alice Bernasconi and Elad Sharon and Riccardo Capocaccia and Angela B. Mariotto and},
    volume = {9},
    year = {2020},
    doi = {10.1002/cam4.3137},
    journal = {Cancer Medicine},
    pages = {5632--5642},
    publisher = {Wiley},
    relevance = {relevant},
    number = {15},
}

@article{Boyd2016,
    publisher = {Elsevier {BV}},
    relevance = {relevant},
    pages = {e52--e61},
    author = {Niki Boyd and Janet E Dancey and C Blake Gilks and David G Huntsman},
    title = {Rare cancers: a sea of opportunity},
    doi = {10.1016/s1470-2045(15)00386-1},
    year = {2016},
    volume = {17},
    month = {feb},
    number = {2},
    journal = {The Lancet Oncology},
}

@article{Brade2016,
    author = {Anthony M. Brade and Laura Ann Dawson},
    doi = {10.1200/jco.2015.63.8767},
    year = {2016},
    number = {3},
    month = {jan},
    title = {To {RCT} or Not to {RCT}: How to Change Practice for Rare Cancers?},
    publisher = {American Society of Clinical Oncology ({ASCO})},
    journal = {Journal of Clinical Oncology},
    pages = {203--204},
    volume = {34},
}

@article{Braiteh2007,
    journal = {Molecular Cancer Therapeutics},
    pages = {1175--1179},
    author = {Fadi Braiteh and Razelle Kurzrock},
    doi = {10.1158/1535-7163.mct-06-0674},
    publisher = {American Association for Cancer Research ({AACR})},
    month = {apr},
    number = {4},
    readstatus = {read},
    title = {Uncommon tumors and exceptional therapies: paradox or paradigm?},
    volume = {6},
    year = {2007},
}

@article{Bray201948,
    readstatus = {skimmed},
    url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85100249804&partnerID=40&md5=0443aae6676afb68d23b026fdc1347fe},
    year = {2019},
    note = {Cited by: 1},
    publication_stage = {Final},
    title = {Overview of geographical diversity},
    journal = {The Cancer Atlas},
    pages = {48 – 49},
    author = {Bray, F. and Soerjomataram, I.},
}

@article{brennan2010pediatric,
    pages = {659--660},
    number = {54},
    url = {https://ar.art1lib.org/book/5391789/67ae7b},
    volume = {5},
    journal = {Pediatric blood \& cancer},
    author = {Brennan, Bernadette},
    title = {Pediatric pancreatic tumors: the orphan looking for a home},
    year = {2010},
}

@article{Buller2021,
    number = {3},
    author = {Ian D Buller and Rena R Jones},
    doi = {10.1093/aje/kwab285},
    journal = {American Journal of Epidemiology},
    month = {dec},
    pages = {499--502},
    readstatus = {read},
    year = {2021},
    volume = {191},
    publisher = {Oxford University Press ({OUP})},
    title = {Invited Commentary: Predicting Incidence Rates of Rare Cancers{\textemdash}Adding Epidemiologic and Spatial Contexts},
}

@article{bustamante-teixeira_incidence_2019,
    shortjournal = {Tumori},
    title = {Incidence of rare cancers in the city of São Paulo, Brazil},
    url = {http://journals.sagepub.com/doi/10.1177/0300891618821039},
    issn = {0300-8916, 2038-2529},
    abstract = {Introduction:
Rare cancers are a challenge for clinical practice as well as for epidemiology and public health. Studies on this subject are few and limited to the study of cases with scarce epidemiologic information. This study aimed to evaluate the incidence of rare cancers and to compare the demographic, anatomic, and histologic characteristics of rare and nonrare (common) cancers.


Methods:
Incidence data were obtained from the Population-based Cancer Registry of São Paulo, Brazil. Rare neoplasms were those defined in the {RARECARE} list, which takes into account an incidence lower than 6/100,000/year.


Results:
In São Paulo, 20.4\% of tumors had an incidence lower than 6/100,000/year from 1997 to 2012, being therefore considered as rare tumors. We identified 11 entities with an incidence greater than 6/100,000/year (common neoplasms) and 186 entities with an incidence lower than 6/100,000/year (rare neoplasms). The mean annual incidence of all cancers was 365 per 100,000 in São Paulo between 1997 and 2012, and the incidence of all rare tumors was 74.5 per 100,000.


Conclusions:
This study presents the burden of rare cancers in Brazil. It is expected to be an incentive for further studies of these entities in order to know the epidemiologic profile of rare tumors in Brazil and to provide a more effective diagnostic and therapeutic approach.},
    date = {2019-02},
    pages = {22--30},
    author = {Bustamante-Teixeira, Maria Teresa and Latorre, Maria do Rosário D.O. and Guerra, Maximiliano R. and Tanaka, Luana F. and Botta, Laura and Trama, Annalisa and Gatta, Gemma},
    journaltitle = {Tumori Journal},
    langid = {english},
    volume = {105},
    number = {1},
    urldate = {2022-05-17},
    doi = {10.1177/0300891618821039},
    qualityassured = {qualityAssured},
}

@article{capocaccia2002measuring,
    date = {2002-06-13},
    journal = {Ann Oncol},
    title = {Measuring cancer prevalence in Europe: the EUROPREVAL project},
    pmid = {12123329},
    note = {PMID: 12123329.},
    author = {Capocaccia, R. and Colonna, M. and Corazziari, I. and Angelis, R. and Francisci, S. and Micheli, A. and Mugno, E. and Group, E.U.R.O.P.R.E.V.A.L.Working},
    language = {en},
    doi = {10.1093/annonc/mdf152.},
}

@article{Casali2010,
    journal = {The Lancet Oncology},
    title = {Do rare cancers deserve specific strategies for cancer research?},
    month = {jun},
    pages = {506--507},
    volume = {11},
    doi = {10.1016/s1470-2045(10)70099-1},
    publisher = {Elsevier {BV}},
    author = {Paolo G Casali},
    number = {6},
    year = {2010},
}

@article{Casali2014,
    author = {P.G. Casali},
    journal = {Annals of Oncology},
    pages = {914},
    month = {apr},
    publisher = {Elsevier {BV}},
    year = {2014},
    doi = {10.1093/annonc/mdu033},
    volume = {25},
    title = {Rare cancers: work in progress in Europe},
    number = {4},
}

@article{Casali2015,
    volume = {26},
    year = {2015},
    doi = {10.1093/annonc/mdu459},
    month = {feb},
    author = {P.G. Casali and P. Bruzzi and J. Bogaerts and J.-Y. Blay and M. Aapro and A. Adamous and A. Berruti and J.-Y. Blay and J. Bogaerts and J. Bressington and B. Bruzzi and R. Capocaccia and F. Cardoso and P.G. Casali and J.E. Celis and A. Cervantes and F. Ciardiello and C. Claussen and M. Coleman and S. Comis and S. Craine and D. De Boltz and F. De Lorenzo and A.P. Dei Tos and G. Gatta and J. Geissler and R. Giuliani and E. Grande and A. Gronchi and S. Jezdic and B. Jonsson and L. Jost and H. Keulen and D. Lacombe and G. Lamory and Y. Le Cam and S. Leto di Priolo and L. Licitra and F. Macchia and A. Margulies and S. Marreaud and G. McVie and S. Narbutas and K. Oliver and N. Pavlidis and J. Pelouchova and G. Pentheroudakis and M. Piccart and M.A. Pierotti and G. Pravettoni and K. Redmond and P. Riegman and M.P. Ruffilli and D. Ryner and S. Sandrucci and M. Seymour and V. Torri and A. Trama and S. Van Belle and G. Vassal and M. Wartenberg and C. Watts and A. Wilson and W. Yared},
    journal = {Annals of Oncology},
    publisher = {Elsevier {BV}},
    pages = {300--306},
    title = {Rare Cancers Europe ({RCE}) methodological recommendations for clinical studies in rare cancers: a European consensus position paper},
    number = {2},
}

@article{Casali2019,
    year = {2019},
    month = {jul},
    number = {7},
    doi = {10.1093/annonc/mdz146},
    publisher = {Elsevier {BV}},
    journal = {Annals of Oncology},
    volume = {30},
    author = {P.G. Casali},
    title = {Rare cancers: from centralized referral to networking},
    pages = {1037--1038},
}

@article{Casali2020,
    journaltitle = {{ESMO} Open},
    journal = {{ESMO} Open},
    readstatus = {read},
    langid = {english},
    urldate = {2022-05-17},
    number = {2},
    year = {2020},
    shortjournal = {{ESMO} Open},
    qualityassured = {qualityAssured},
    url = {https://linkinghub.elsevier.com/retrieve/pii/S2059702920300648},
    publisher = {Elsevier {BV}},
    date = {2020},
    title = {Rationale of the rare cancer list: a consensus paper from the Joint Action on Rare Cancers ({JARC}) of the European Union ({EU})},
    author = {Casali, Paolo G. and Trama, Annalisa},
    issn = {20597029},
    ranking = {rank5},
    pages = {e000666},
    volume = {5},
    doi = {10.1136/esmoopen-2019-000666},
}

@article{Casali2022,
    author = {Paolo G. Casali and Salvatore Provenzano and Annalisa Trama},
    doi = {10.1701/3850.38337},
    year = {2022},
    title = {Il problema dei tumori rari},
    publisher = {Il Pensiero Scientifico Editore},
    journal = {Recenti Progressi in Medicina},
}

@article{casali_rare_2022,
    qualityassured = {qualityAssured},
    langid = {english},
    title = {‘Rare cancers’: not all together in clinical studies!},
    shorttitle = {‘Rare cancers’},
    urldate = {2022-05-17},
    pages = {463--465},
    url = {https://linkinghub.elsevier.com/retrieve/pii/S0923753422001041},
    number = {5},
    author = {Casali, P.G. and Licitra, L. and Frezza, A.M. and Trama, A.},
    date = {2022-05},
    doi = {10.1016/j.annonc.2022.01.077},
    shortjournal = {Annals of Oncology},
    issn = {09237534},
    journaltitle = {Annals of Oncology},
    volume = {33},
}

@article{Castaing2016,
    publisher = {Inferenze scarl},
    issn = {1120-9763, 2385-1937},
    pages = {1-120},
    journal = {Epidemiologia & Prevenzione},
    doi = {10.19191/EP16.1S2.P001.035},
    author = {Marine Castaing and Francesca Bella and Rosalba Amodio and Sabrina Bizzoco and Tiziana Cassetti and Claudia Cirilli and Rosanna Cusimano and Roberta De Angelis and Mario Fusco and Gemma Gatta and Valerio Gennaro and Adriano Giacomin and Paolo Giorgi Rossi and Lucia Mangone and Salvatore Mannino and Silvia Rossi and Daniela Pierannunzio and Andrea Tavilla and Sandro Tognazzo and Rosario Tumino and Massimo Vicentini and Maria Francesca Vitale},
    title = {I tumori in Italia - Rapporto 2015: I tumori rari in Italia},
    volume = {40},
    year = {2016},
}

@article{Chabner1992,
    year = {1992},
    pages = {563--565},
    publisher = {Massachusetts Medical Society},
    readstatus = {read},
    title = {Progress against Rare and Not-So-Rare Cancers},
    volume = {326},
    author = {Bruce A. Chabner and Michael A. Friedman},
    journal = {New England Journal of Medicine},
    month = {feb},
    number = {8},
    doi = {10.1056/nejm199202203260811},
}

@article{Charbotel2014,
    relevance = {relevant},
    pages = {99--134},
    journal = {Critical Reviews in Oncology/Hematology},
    publisher = {Elsevier {BV}},
    doi = {10.1016/j.critrevonc.2013.12.004},
    month = {may},
    author = {B. Charbotel and B. Fervers and J.P. Droz},
    volume = {90},
    number = {2},
    year = {2014},
    title = {Occupational exposures in rare cancers: A critical review of the literature},
}

@article{Chawla2022,
    journal = {Value in Health},
    author = {A Chawla and H Patel and R Folorunso},
    number = {7},
    readstatus = {read},
    publisher = {Elsevier {BV}},
    month = {jul},
    ranking = {rank2},
    pages = {S512},
    title = {{HTA}45 Care for Rare: Market Access Evidentiary Requirements for Rare Cancers},
    volume = {25},
    year = {2022},
    doi = {10.1016/j.jval.2022.04.1177},
}

@article{Choi2010,
    journal = {New England Journal of Medicine},
    volume = {363},
    month = {oct},
    publisher = {Massachusetts Medical Society},
    doi = {10.1056/nejmoa1007478},
    year = {2010},
    title = {{EML}4-{ALK} Mutations in Lung Cancer That Confer Resistance to {ALK} Inhibitors},
    number = {18},
    pages = {1734--1739},
    author = {Young Lim Choi and Manabu Soda and Yoshihiro Yamashita and Toshihide Ueno and Junpei Takashima and Takahiro Nakajima and Yasushi Yatabe and Kengo Takeuchi and Toru Hamada and Hidenori Haruta and Yuichi Ishikawa and Hideki Kimura and Tetsuya Mitsudomi and Yoshiro Tanio and Hiroyuki Mano},
}

@article{Cohen2018,
    publisher = {{BMJ}},
    author = {Deborah Cohen},
    pages = {k5401},
    year = {2018},
    doi = {10.1136/bmj.k5401},
    title = {Breast implants linked to rare cancer are removed from European market},
    month = {dec},
    journal = {{BMJ}},
}

@article{DArcy2020,
    publisher = {Oxford University Press ({OUP})},
    author = {Monica E D'Arcy and David Castenson and Charles F Lynch and Amy R Kahn and Lindsay M Morton and Meredith S Shiels and Ruth M Pfeiffer and Eric A Engels},
    year = {2020},
    title = {Risk of Rare Cancers Among Solid Organ Transplant Recipients},
    journal = {{JNCI}: Journal of the National Cancer Institute},
    month = {may},
    doi = {10.1093/jnci/djaa078},
}

@article{Darling2020,
    publication_stage = {Final},
    journal = {Indian Journal of Cancer},
    note = {Cited by: 3},
    author = {Darling, H.S. and Rastogi, Sameer},
    pages = {139 – 143},
    title = {Rare cancers in India: A road less travelled},
    year = {2020},
    doi = {10.4103/ijc.IJC-384-19},
    number = {2},
    url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85085242767&doi=10.4103%2fijc.IJC-384-19&partnerID=40&md5=e0081f2e99af20a09bba53b36ddfe165},
    volume = {57},
}

@article{de2009eurocare,
    author = {De Angelis, Roberta and Francisci, Silvia and Baili, Paolo and Marchesi, Francesca and Roazzi, Paolo and Belot, Aur{\'e}lien and Crocetti, Emanuele and Pury, Pierre and Knijn, Arnold and Coleman, Michel and others},
    month = {apr},
    title = {The EUROCARE-4 database on cancer survival in Europe: data standardisation, quality control and methods of statistical analysis},
    year = {2009},
    doi = {10.1016/j.ejca.2008.11.003},
    pages = {909--930},
    publisher = {Elsevier},
    number = {6},
    volume = {45},
    journal = {European Journal of Cancer},
}

@article{de_heus_differences_2021,
    urldate = {2022-05-17},
    volume = {16},
    langid = {english},
    date = {2021-12},
    url = {https://ojrd.biomedcentral.com/articles/10.1186/s13023-021-01886-2},
    abstract = {Abstract

Background
Patients with rare cancers face challenges in the diagnostic and treatment phase, and in access to clinical expertise. Since studies on health care experiences of these patients in comparison to patients with more common cancers are scarce, we aimed to explore these differences.


Methods
Data were cross-sectionally collected among (former) adult cancer patients through a national online survey in the Netherlands (October 2019). Descriptive statistics were reported and subgroups (rare vs. common patients) were compared.


Results

In total, 7343 patients (i.e., 1856 rare and 5487 common cancer patients) participated. Rare cancer patients were more often diagnosed and treated in different hospitals compared to common cancer patients (67\% vs. 59\%,
p
{\textless} 0.001). Rare cancer patients received treatment more often in a single hospital (60\% vs. 57\%,
p
= 0.014), but reported more negative experiences when treated in multiple hospitals than common cancer patients (14\% vs. 9\%,
p
{\textless} 0.001). They also more often received advise from their physician about the hospital to go to for a second opinion (50\% vs. 36\%,
p
{\textless} 0.001), were more likely to choose a hospital specialized in their cancer type (33\% vs. 22\%,
p
{\textless} 0.001), and were more willing to travel as long as necessary to receive specialized care than common cancer patients (55\% vs. 47\%,
p
{\textless} 0.001).



Conclusions
Rare and common cancer patients differ in their health care experiences. Health care for rare cancer patients can be further improved by proper referral to centers of expertise and building a clinical network specifically for rare cancers.},
    number = {1},
    issn = {1750-1172},
    file = {:de_heus_differences_2021 - Differences in Health Care Experiences between Rare Cancer and Common Cancer Patients_ Results from a National Cross Sectional Survey.pdf:PDF;Full Text:C\:/Users/Kostadin/Zotero/storage/8UUPFCZW/de Heus и др. - 2021 - Differences in health care experiences between rar.pdf:application/pdf},
    shorttitle = {Differences in health care experiences between rare cancer and common cancer patients},
    author = {de Heus, Eline and Engelen, Vivian and Dingemans, Irene and Richel, Carol and Schrieks, Marga and van der Zwan, Jan Maarten and Besselink, Marc G. and van Berge Henegouwen, Mark I. and van Herpen, Carla M. L. and Duijts, Saskia F. A.},
    doi = {10.1186/s13023-021-01886-2},
    title = {Differences in health care experiences between rare cancer and common cancer patients: results from a national cross-sectional survey},
    readstatus = {read},
    qualityassured = {qualityAssured},
    shortjournal = {Orphanet J Rare Dis},
    ranking = {rank2},
    pages = {249},
    journaltitle = {Orphanet Journal of Rare Diseases},
}

@inproceedings{Delikoyun2021,
    year = {2021},
    doi = {10.1117/12.2572908},
    title = {Label-free detection of rare cancer cells using deep learning and magnetic levitation principle},
    booktitle = {Label-free Biomedical Imaging and Sensing ({LBIS}) 2021},
    author = {Kerem Delikoyun and Ali Aslan Demir and Huseyin Cumhur Tekin},
    month = {mar},
    editor = {Natan T. Shaked and Oliver Hayden},
    publisher = {{SPIE}},
}

@incollection{Demeure2019,
    title = {The Role of Precision Medicine in the Diagnosis and Treatment of Patients with Rare Cancers},
    author = {Michael J. Demeure},
    booktitle = {Precision Medicine in Cancer Therapy},
    doi = {10.1007/978-3-030-16391-4_3},
    pages = {81--108},
    publisher = {Springer International Publishing},
    year = {2019},
}

@article{derzwan,
    author = {der Zwan, Jan Maarten},
    readstatus = {read},
    url = {https://iknl.nl/getmedia/7dd6f5b1-ae16-4143-9105-38a1f25f0965/proefschrift-jan-maarten-van-der-zwan-surveillance-of-rare-cancers.pdf},
    title = {Survailliance of rare cancer},
    year = {2021},
}

@article{DeSantis2017,
    author = {{DeSantis}, Carol E. and Kramer, Joan L. and Jemal, Ahmedin},
    qualityassured = {qualityAssured},
    number = {4},
    issn = {00079235},
    pages = {261--272},
    month = {may},
    shorttitle = {The burden of rare cancers in the United States},
    urldate = {2022-05-17},
    journal = {{CA}: A Cancer Journal for Clinicians},
    date = {2017-07-08},
    year = {2017},
    volume = {67},
    doi = {10.3322/caac.21400},
    file = {Full Text:C\:\\Users\\Kostadin\\Zotero\\storage\\R9T5S86E\\DeSantis и др. - 2017 - The burden of rare cancers in the United States T.pdf:application/pdf},
    url = {http://doi.wiley.com/10.3322/caac.21400},
    journaltitle = {{CA}: A Cancer Journal for Clinicians},
    langid = {english},
    publisher = {Wiley},
    title = {The burden of rare cancers in the United States: The Burden of Rare Cancers in the United States},
    shortjournal = {{CA}: A Cancer Journal for Clinicians},
}

@article{Dijk2012,
    journal = {European Journal of Cancer},
    relevance = {relevant},
    publisher = {Elsevier {BV}},
    doi = {10.1016/j.ejca.2011.08.021},
    title = {Rare cancers of the head and neck area in Europe},
    volume = {48},
    year = {2012},
    author = {B.A.C. Van Dijk and G. Gatta and R. Capocaccia and D. Pierannunzio and P. Strojan and L. Licitra},
    pages = {783--796},
    month = {apr},
    number = {6},
}

@article{duijts_rare_2021,
    shortjournal = {Eur J Cancer Care},
    shorttitle = {Rare cancers and cancer of unknown primary},
    urldate = {2022-05-17},
    file = {Full Text:C\:\\Users\\Kostadin\\Zotero\\storage\\FSWDVGUQ\\Duijts и Zwan - 2021 - Rare cancers and cancer of unknown primary Here's.pdf:application/pdf},
    journaltitle = {European Journal of Cancer Care},
    qualityassured = {qualityAssured},
    title = {Rare cancers and cancer of unknown primary: Here's what you should know!},
    langid = {english},
    author = {Duijts, Saskia F. A. and Zwan, Jan Maarten},
    url = {https://onlinelibrary.wiley.com/doi/10.1111/ecc.13508},
    doi = {10.1111/ecc.13508},
    number = {6},
    readstatus = {read},
    issn = {0961-5423, 1365-2354},
    volume = {30},
    date = {2021-11},
}

@article{dyba2021european,
    journal = {European Journal of Cancer},
    title = {The European cancer burden in 2020: Incidence and mortality estimates for 40 countries and 25 major cancers},
    year = {2021},
    pages = {308--347},
    author = {Dyba, Tadeusz and Randi, Giorgia and Bray, Freddie and Martos, Carmen and Giusti, Francesco and Nicholson, Nicholas and Gavin, Anna and Flego, Manuela and Neamtiu, Luciana and Dimitrova, Nadya and others},
    publisher = {Elsevier},
    volume = {157},
}

@article{Ellis2010,
    number = {1},
    pages = {124--125},
    volume = {67},
    publisher = {Elsevier {BV}},
    journal = {Lung Cancer},
    doi = {10.1016/j.lungcan.2009.10.019},
    author = {Libby Ellis and Jesme Fox and Michael D. Peake and Michel P. Coleman},
    title = {Lung cancer in young women remains rare},
    month = {jan},
    year = {2010},
}

@article{Eslick2012,
    doi = {10.1016/j.hoc.2012.09.002},
    number = {6},
    publisher = {Elsevier {BV}},
    pages = {1137--1141},
    author = {Guy D. Eslick},
    journal = {Hematology/Oncology Clinics of North America},
    volume = {26},
    year = {2012},
    title = {What is a Rare Cancer?},
    month = {dec},
}

@misc{ESMORare82:online,
    publisher = {European society for medical oncology},
    url = {https://www.esmo.org/content/download/16802/296577/1/ESMO_Rare_Cancers_recommendations_2010.pdf},
    title = {Improving Rare Cancer Care in Europe Recommendations on Stakeholder Actions and Public Policies},
    year = {2010},
}

@article{Fair2020,
    number = {1},
    year = {2020},
    file = {:Fair2020 - Challenges and Solutions to the Study of Rare Childhood Tumors.pdf:PDF},
    journal = {Current Opinion in Pediatrics},
    pages = {7--12},
    month = {feb},
    author = {Douglas Fair and Samara L. Potter and Rajkumar Venkatramani},
    volume = {32},
    doi = {10.1097/mop.0000000000000857},
    publisher = {Ovid Technologies (Wolters Kluwer Health)},
    title = {Challenges and solutions to the study of rare childhood tumors},
}

@article{Feldmeyer2013,
    year = {2013},
    doi = {10.1038/jid.2013.90},
    month = {aug},
    number = {8},
    volume = {133},
    journal = {Journal of Investigative Dermatology},
    publisher = {Elsevier {BV}},
    pages = {1929--1932},
    title = {Clinical Implications of {CD}8$\mathplus$ T-Cell Infiltration in Frequent and Rare Cancers},
    author = {Laurence Feldmeyer and Olivier Gaide and Daniel E. Speiser},
}

@article{Ferrari2007,
    year = {2007},
    month = {mar},
    author = {Andrea Ferrari and Gianni Bisogno and Gian Luca De Salvo and Paolo Indolfi and Giorgio Perilongo and Giovanni Cecchetto},
    pages = {654--659},
    doi = {10.1016/j.ejca.2006.08.028},
    number = {4},
    readstatus = {read},
    volume = {43},
    journal = {European Journal of Cancer},
    title = {The challenge of very rare tumours in childhood: The Italian {TREP} project},
    publisher = {Elsevier {BV}},
}

@article{Finkelstein2019,
    number = {1},
    year = {2019},
    doi = {10.1186/s12885-019-5358-1},
    publisher = {Springer Science and Business Media {LLC}},
    volume = {19},
    author = {Dianne M. Finkelstein and Nora K. Horick and Ritesh Ramchandani and Kristina L. Boyd and Huma Q. Rana and Brittany L. Bychkovsky},
    journal = {{BMC} Cancer},
    title = {Are rare cancer survivors at elevated risk of subsequent new cancers?},
    month = {feb},
}

@article{Fiorentino2021,
    author = {Alba Fiorentino and Fabiana Gregucci and Isacco Desideri and Michele Fiore and Lorenza Marino and Angelo Errico and Alessia Di Rito and Paolo Borghetti and Pierfrancesco Franco and Daniela Greto and Vittorio Donato},
    volume = {159},
    pages = {103228},
    year = {2021},
    ranking = {rank1},
    title = {Radiation treatment for adult rare cancers: Oldest and newest indication},
    month = {mar},
    doi = {10.1016/j.critrevonc.2021.103228},
    journal = {Critical Reviews in Oncology/Hematology},
    publisher = {Elsevier {BV}},
    readstatus = {read},
}

@article{Frezza2019,
    doi = {10.1016/j.ejso.2018.03.030},
    number = {1},
    relevance = {relevant},
    title = {Networking in rare cancers: What was done, what is next?},
    year = {2019},
    pages = {16--18},
    author = {Anna Maria Frezza and Annalisa Trama and Jean-Yves Blay and Paolo G. Casali},
    journal = {European Journal of Surgical Oncology},
    month = {jan},
    publisher = {Elsevier {BV}},
    volume = {45},
}

@article{Gaddipati2012,
    author = {Himabindu Gaddipati and Ke Liu and Anne Pariser and Richard Pazdur},
    journal = {Clinical Cancer Research},
    year = {2012},
    volume = {18},
    month = {sep},
    doi = {10.1158/1078-0432.ccr-12-1135},
    pages = {5172--5178},
    number = {19},
    publisher = {American Association for Cancer Research ({AACR})},
    title = {Rare Cancer Trial Design: Lessons from {FDA} Approvals},
}

@article{Gallicchio2021,
    readstatus = {read},
    volume = {30},
    year = {2021},
    publisher = {American Association for Cancer Research ({AACR})},
    title = {Epidemiologic Research of Rare Cancers: Trends, Resources, and Challenges},
    author = {Lisa Gallicchio and Danielle L. Daee and Melissa Rotunno and Rolando Barajas and Sarah Fagan and Danielle M. Carrick and Rao L. Divi and Kelly K. Filipski and Andrew N. Freedman and Elizabeth M. Gillanders and Tram K. Lam and Damali N. Martin and Scott Rogers and Mukesh Verma and Stefanie A. Nelson},
    doi = {10.1158/1055-9965.epi-20-1796},
    pages = {1305--1311},
    ranking = {rank5},
    journal = {Cancer Epidemiology, Biomarkers {\&}amp$\mathsemicolon$ Prevention},
    month = {apr},
    number = {7},
}

@article{Gatta2006,
    volume = {7},
    author = {Gemma Gatta and Laura Ciccolallo and Ian Kunkler and Riccardo Capocaccia and Franco Berrino and Michel P Coleman and Roberta De Angelis and Jean Faivre and Jean Michel Lutz and Carmen Martinez and Torgil Möller and Risto Sankila},
    pages = {132--140},
    journal = {The Lancet Oncology},
    title = {Survival from rare cancer in adults: a population-based study},
    doi = {10.1016/s1470-2045(05)70471-x},
    month = {feb},
    publisher = {Elsevier {BV}},
    year = {2006},
    readstatus = {read},
    number = {2},
}

@article{gatta2010burden,
    readstatus = {read},
    pages = {285--303},
    doi = {https://doi.org/10.1007/978-90-481-9485-8_17},
    relevance = {relevant},
    year = {2010},
    author = {Gatta, Gemma and Capocaccia, Riccardo and Trama, Annalisa and Mart{\'\i}nez-Garc{\'\i}a, Carmen},
    title = {The burden of rare cancers in Europe},
    booktitle = {Rare Diseases Epidemiology},
    journal = {Rare Diseases Epidemiology},
    publisher = {Springer Netherlands},
}

@article{Gatta2019,
    pages = {3--11},
    doi = {10.1016/j.ejso.2017.08.018},
    publisher = {Elsevier {BV}},
    relevance = {relevant},
    author = {G. Gatta and A. Trama and R. Capocaccia and Monika Hackl and Elizabeth Van Eycken and Kris Henau and Nadya Dimitrova and Mario Sekerija and Ladislav Du{\v{s}}ek and Margit Mägi and Nea Malila and Maarit Leinonen and Michel Velten and Xavier Troussard and Veronique Bouvier and Anne-Val{\'{e}}rie Guizard and Anne-Marie Bouvier and Patrick Arveux and Marc Maynadi{\'{e}} and Anne-Sophie Woronoff and Michel Robaszkiewicz and Isabelle Baldi and Alain Monnereau and Brigitte Tretarre and Marc Colonna and Florence Molini{\'{e}} and Simona Bara and Claire Schvartz and B{\'{e}}n{\'{e}}dicte Lap{\^{o}}tre-Ledoux and Pascale Grosclaude and Roland Stabenow and Sabine Luttmann and Alice Nennecke and Jutta Engel and Gabriele Schubert-Fritschle and Jan Heidrich and Bernd Holleczek and J{\'{o}}n Gunnlaugur J{\'{o}}nasson and Kerri Clough-Gorr and Harry Comber and Guido Mazzoleni and Adriano Giacomin and Antonella Sutera Sardo and Alessandro Barchielli and Diego Serraino and Roberta De Angelis and Sandra Mallone and Andrea Tavilla and Daniela Pierannunzio and Silvia Rossi and Mariano Santaquilani and Arnold Knijn and Fabio Pannozzo and Valerio Gennaro and Lucia Benfatto and Paolo Ricci and Mariangela Autelitano and Gianbattista Spagnoli and Mario Fusco and Mario Usala and Francesco Vitale and Maria Michiara and Rosario Tumino and Lucia Mangone and Fabio Falcini and Stefano Ferretti and Rosa Angela Filiberti and Enza Marani and Arturo Iannelli and Flavio Sensi and Silvano Piffer and Maria Gentilini and Anselmo Madeddu and Antonio Ziino and Sergio Maspero and Pina Candela and Fabrizio Stracci and Giovanna Tagliabue and Massimo Rugge and Annalisa Trama and Gemma Gatta and Laura Botta and Riccardo Capocaccia and Santa Pildava and Giedre Smailyte and Neville Calleja and Tom B{\o}rge Johannesen and Jadwiga Rachtan and Stanis{\l}aw G{\'{o}}{\'{z}}d{\'{z}} and Jerzy B{\l}aszczyk and Kamila K{\k{e}}pska and Forjaz de Lacerda and Maria Jos{\'{e}} Bento and Ana Miranda and Chakameh Safaei Diba and Enrique Almar and Nerea Larra{\~{n}}aga and Arantza Lopez de Munain and Ana Torrella-Ramos and Jos{\'{e}} Mar{\'{\i}}a D{\'{\i}}az Garc{\'{\i}}a and Rafael Marcos-Gragera and Maria Jos{\`{e}} Sanchez and Carmen Navarro and Diego Salmeron and Conchi Moreno-Iribas and Jaume Galceran and Mari{\`{a}} Carulla and Mohsen Mousavi and Christine Bouchardy and Silvia M. Ess and Andrea Bordoni and Isabelle Konzelmann and Jem Rashbass and Anna Gavin and David H. Brewster and Dyfed Wyn Huws and Otto Visser and Magdalena Bielska-Lasota and Maja Primic-Zakelj and Ian Kunkler and Ellen Benhamou},
    journal = {European Journal of Surgical Oncology},
    month = {jan},
    number = {1},
    volume = {45},
    year = {2019},
    title = {Epidemiology of rare cancers and inequalities in oncologic outcomes},
}

@article{gatta_burden_2017,
    urldate = {2022-05-17},
    shortjournal = {The Lancet Oncology},
    shorttitle = {Burden and centralised treatment in Europe of rare tumours},
    title = {Burden and centralised treatment in Europe of rare tumours: results of {RARECAREnet}—a population-based study},
    url = {https://linkinghub.elsevier.com/retrieve/pii/S147020451730445X},
    author = {Gatta, Gemma and Capocaccia, Riccardo and Botta, Laura and Mallone, Sandra and De Angelis, Roberta and Ardanaz, Eva and Comber, Harry and Dimitrova, Nadya and Leinonen, Maarit K and Siesling, Sabine and van der Zwan, Jan M and Van Eycken, Liesbet and Visser, Otto and Žakelj, Maja P and Anderson, Lesley A and Bella, Francesca and Kaire, Innos and Otter, Renée and Stiller, Charles A and Trama, Annalisa and Hackl, Monika and Henau, Kris and Van Damme, Nancy and Valerianova, Zdravka and Sekerija, Mario and Dušek, Ladislav and Mägi, Margit and Paapsi, Keiu and Malila, Nea and Velten, Michel and Troussard, Xavier and Bouvier, Veronique and Guizard, Anne-Valérie and Bouvier, Anne-Marie and Arveux, Patrick and Maynadié, Marc and Woronoff, Anne-Sophie and Robaszkiewicz, Michel and Baldi, Isabelle and Monnereau, Alain and Tretarre, Brigitte and Colonna, Marc and Molinié, Florence and Bara, Simona and Schvartz, Claire and Lapôtre-Ledoux, Bénédicte and Grosclaude, Pascale and Stabenow, Roland and Luttmann, Sabine and Nennecke, Alice and Engel, Jutta and {SchubertFritschle}, Gabriele and Heidrich, Jan and Holleczek, Bernd and Jónasson, Jón Gunnlaugur and Clough-Gorr, Kerri and Mazzoleni, Guido and Giacomin, Adriano and Sardo, Antonella Sutera and Barchielli, Alessandro and Serraino, Diego and Collarile, Paolo and Pannozzo, Fabio and Ricci, Paolo and Autelitano, Mariangela and Spagnoli, Gianbattista and Fusco, Mario and Usala, Mario and Vitale, Francesco and Michiara, Maria and Tumino, Rosario and Mangone, Lucia and Falcini, Fabio and Ferretti, Stefano and Filiberti, Rosa Angela and Marani, Enza and Caiazzo, Anna Luisa and Iannelli, Arturo and Sensi, Flavio and Piffer, Silvano and Gentilini, Maria and Madeddu, Anselmo and Colanino, Antonino Ziino and Maspero, Sergio and Candela, Pina and Stracci, Fabrizio and Tagliabue, Giovanna and Rugge, Massimo and Baili, Paolo and Minicozzi, Pamela and Sant, Milena and Tereanu, Carmen and Francisci, Silvia and Tavilla, Andrea and Pierannunzio, Daniela and Rossi, Silvia and Santaquilani, Mariano and Knijn, Arnold and Pildava, Santa and Smailyte, Giedre and Calleja, Neville and Agius, Dominic and Johannesen, Tom Børge and Rachtan, Jadwiga and Gózdz, Stanislaw and Blaszczyk, Jerzy and Kepska, Kamila and Lacerda, Gonçalo Forjaz de and Bento, Maria José and Miranda, Ana and Diba, Chakameh Safaei and Žagar, Tina and Almar, Enrique and Larrañaga, Nerea and Munain, Arantza Lopez de and Torrella-Ramos, Ana and García, José María Díaz and Marcos-Gragera, Rafael and Sanchez, Maria Josè and Navarro, Carmen and Salmeron, Diego and Moreno-Iribas, Conchi and Galceran, Jaume and Carulla, Marià and Mousavi, Mohsen and Bouchardy, Christine and Ess, Silvia M. and Bordoni, Andrea and Konzelmann, Isabelle and Rashbass, Jem and Gavin, Anna and Brewster, David H and Huws, Dyfed Wyn and Ho, Vincent {KY} and Benhamou, Ellen},
    doi = {10.1016/S1470-2045(17)30445-X},
    volume = {18},
    number = {8},
    file = {Full Text:C\:\\Users\\Kostadin\\Zotero\\storage\\TYTFXY5X\\Gatta и др. - 2017 - Burden and centralised treatment in Europe of rare.pdf:application/pdf},
    issn = {14702045},
    langid = {english},
    journaltitle = {The Lancet Oncology},
    date = {2017-08},
    pages = {1022--1039},
    qualityassured = {qualityAssured},
}

@article{gatta_rare_2011,
    number = {17},
    title = {Rare cancers are not so rare: The rare cancer burden in Europe},
    shorttitle = {Rare cancers are not so rare},
    author = {Gatta, Gemma and van der Zwan, Jan Maarten and Casali, Paolo G. and Siesling, Sabine and Dei Tos, Angelo Paolo and Kunkler, Ian and Otter, Renée and Licitra, Lisa and Mallone, Sandra and Tavilla, Andrea and Trama, Annalisa and Capocaccia, Riccardo},
    journaltitle = {European Journal of Cancer},
    doi = {10.1016/j.ejca.2011.08.008},
    pages = {2493--2511},
    volume = {47},
    langid = {english},
    shortjournal = {European Journal of Cancer},
    date = {2011-11},
    issn = {09598049},
    qualityassured = {qualityAssured},
    url = {https://linkinghub.elsevier.com/retrieve/pii/S0959804911006083},
    urldate = {2022-05-17},
}

@article{Gladdy2021,
    year = {2021},
    journal = {Annals of Oncology},
    month = {nov},
    doi = {10.1016/j.annonc.2021.08.2155},
    pages = {1325--1326},
    volume = {32},
    number = {11},
    author = {R.A. Gladdy},
    title = {Precision guidelines for soft tissue and visceral sarcomas: the evidence, expert experience and ensuring optimal care for rare cancers, a 2021 update from {ESMO}{\textendash}{EURACAN}{\textendash}{GENTURIS}},
    publisher = {Elsevier {BV}},
}

@article{Gonzato2016,
    volume = {8},
    year = {2016},
    author = {Ornella Gonzato},
    doi = {10.1016/j.jcpo.2016.04.001},
    publisher = {Elsevier {BV}},
    month = {jun},
    journal = {Journal of Cancer Policy},
    pages = {38--41},
    title = {Could information improve patient access to new emerging drugs in rare cancer trials?},
}

@article{Gonzato2017,
    volume = {12},
    year = {2017},
    title = {The new risk-sharing paradigm in rare cancers: Patient perspective},
    journal = {Journal of Cancer Policy},
    author = {Ornella Gonzato},
    doi = {10.1016/j.jcpo.2017.03.007},
    pages = {36--42},
    publisher = {Elsevier {BV}},
    month = {jun},
}

@article{graf_von_der_schulenburg_rare_2017,
    urldate = {2022-05-17},
    volume = {11},
    author = {Graf von der Schulenburg, J.-Matthias and Pauer, Frédéric},
    date = {2017-03},
    journaltitle = {Journal of Cancer Policy},
    pages = {54--59},
    langid = {english},
    qualityassured = {qualityAssured},
    shortjournal = {Journal of Cancer Policy},
    title = {Rare cancers—Rarity as a cost and value argument},
    url = {https://linkinghub.elsevier.com/retrieve/pii/S2213538316300194},
    doi = {10.1016/j.jcpo.2016.09.004},
    issn = {22135383},
}

@article{Gramaca2021,
    volume = {200},
    year = {2021},
    month = {apr},
    publisher = {Elsevier {BV}},
    doi = {10.1016/s0049-3848(21)00172-9},
    journal = {Thrombosis Research},
    title = {{PO}-102 Bleeding management challenges in rare cancer-associated thrombosis: a case report of inferior vena cava thrombus in a patient with testicular germ cell tumour},
    pages = {S74--S75},
    author = {J. Grama{\c{c}}a and D.D. Machado and T. Ponte and I. Pina},
}

@article{Grant2010,
    author = {W. B. Grant},
    publisher = {Oxford University Press ({OUP})},
    pages = {1210--1211},
    title = {Re: "Overview of the Cohort Consortium Vitamin D Pooling Project of Rarer Cancers"},
    year = {2010},
    number = {10},
    journal = {American Journal of Epidemiology},
    doi = {10.1093/aje/kwq301},
    month = {sep},
    volume = {172},
}

@article{greenlee_occurrence_2010,
    pages = {28--43},
    file = {:greenlee_occurrence_2010 - The Occurrence of Rare Cancers in U.S. Adults, 1995–2004.pdf:PDF},
    langid = {english},
    title = {The Occurrence of Rare Cancers in U.S. Adults, 1995–2004},
    date = {2010-01},
    url = {http://journals.sagepub.com/doi/10.1177/003335491012500106},
    journaltitle = {Public Health Reports},
    qualityassured = {qualityAssured},
    issn = {0033-3549, 1468-2877},
    volume = {125},
    shortjournal = {Public Health Rep},
    readstatus = {read},
    urldate = {2022-05-17},
    doi = {10.1177/003335491012500106},
    number = {1},
    author = {Greenlee, Robert T. and Goodman, Marc T. and Lynch, Charles F. and Platz, Charles E. and Havener, Lori A. and Howe, Holly L.},
    abstract = {Objective.
Rare cancers have been traditionally understudied, reducing the progress of research and hindering decisions for patients, physicians, and policy makers. We evaluated the descriptive epidemiology of rare cancers using a large, representative, population-based dataset from cancer registries in the United States.


Methods.
We analyzed more than 9 million adult cancers diagnosed from 1995 to 2004 in 39 states and two metropolitan areas using the Cancer in North America ({CINA}) dataset, which covers approximately 80\% of the U.S. population. We applied an accepted cancer classification scheme and a published definition of rare (i.e., fewer than 15 cases per 100,000 per year). We calculated age-adjusted incidence rates and rare/non-rare incidence rate ratios using {SEER}*Stat software, with analyses stratified by gender, age, race/ethnicity, and histology.


Results.
Sixty of 71 cancer types were rare, accounting for 25\% of all adult tumors. Rare cancers occurred with greater relative frequency among those who were younger, nonwhite, and of Hispanic ethnicity than among their older, white, or non-Hispanic counterparts.


Conclusions.
Collectively, rare tumors account for a sizable portion of adult cancers, and disproportionately affect some demographic groups. Maturing population-based cancer surveillance data can be an important source for research on rare cancers, potentially leading to a greater understanding of these cancers and eventually to improved treatment, control, and prevention.},
}

@article{Griffiths2007,
    pages = {434--441},
    publisher = {Elsevier {BV}},
    month = {dec},
    year = {2007},
    doi = {10.1016/j.ejon.2007.09.004},
    journal = {European Journal of Oncology Nursing},
    author = {Jane Griffiths and Carole Willard and Andrea Burgess and Ziv Amir and Karen Luker},
    number = {5},
    readstatus = {read},
    title = {Meeting the ongoing needs of survivors of rarer cancer},
    volume = {11},
}

@article{Griggs2009,
    year = {2009},
    month = {jan},
    number = {1},
    journal = {Molecular Genetics and Metabolism},
    author = {Robert C. Griggs and Mark Batshaw and Mary Dunkle and Rashmi Gopal-Srivastava and Edward Kaye and Jeffrey Krischer and Tan Nguyen and Kathleen Paulus and Peter A. Merkel},
    doi = {10.1016/j.ymgme.2008.10.003},
    volume = {96},
    title = {Clinical research for rare disease: Opportunities, challenges, and solutions},
    publisher = {Elsevier {BV}},
    pages = {20--26},
    readstatus = {read},
}

@article{Gronchi2016,
    volume = {64},
    pages = {113--115},
    publisher = {Elsevier {BV}},
    year = {2016},
    journal = {European Journal of Cancer},
    doi = {10.1016/j.ejca.2016.05.025},
    month = {sep},
    title = {Cancer registries and randomised clinical trials in rare tumours: At the two extremes of daily clinical practice},
    author = {Alessandro Gronchi and Rick L. Haas and Sylvie Bonvalot},
}

@article{Gronchi2016a,
    month = {jun},
    author = {Alessandro Gronchi and Paolo Delrio and Vittorio Quagliuolo and Sergio Sandrucci},
    volume = {68},
    pages = {321--323},
    publisher = {Springer Science and Business Media {LLC}},
    title = {The Italian Society of Surgical Oncology ({SICO}) survey on the minimum requirements of rare cancers referral centers},
    year = {2016},
    journal = {Updates in Surgery},
    doi = {10.1007/s13304-016-0376-x},
    number = {4},
}

@article{Gu2019,
    publisher = {Elsevier {BV}},
    volume = {30},
    doi = {10.1093/annonc/mdz305.002},
    journal = {Annals of Oncology},
    month = {oct},
    pages = {vi8},
    author = {Hongfei Gu},
    title = {Rare Cancers China Programs starting up},
    year = {2019},
}

@article{Guenel2004,
    month = {aug},
    title = {Alcohol Drinking May Increase Risk of Breast Cancer in Men: A European Population-Based Case{\textendash}Control Study},
    number = {6},
    journal = {Cancer Causes {\&}amp$\mathsemicolon$ Control},
    author = {Pascal Gu{\'{e}}nel and Diane Cyr and Svend Sabroe and Elsebeth Lynge and Franco Merletti and Wolfgang Ahrens and Cornelia Baumgardt-Elms and Fran{\c{c}}ois M{\'{e}}n{\'{e}}goz and H{\aa}kan Olsson and Stein Paulsen and Lorenzo Simonato and Gun Wingren},
    pages = {571--580},
    volume = {15},
    year = {2004},
    publisher = {Springer Science and Business Media {LLC}},
    doi = {10.1023/b:caco.0000036154.18162.43},
}

@article{Heus2021,
    langid = {english},
    shortjournal = {Eur J Cancer Care},
    author = {Heus, Eline and Zwan, Jan Maarten and Husson, Olga and Frissen, Anne‐Roos and Herpen, Carla M. L. and Merkx, Matthias A. W. and Duijts, Saskia F. A.},
    qualityassured = {qualityAssured},
    readstatus = {read},
    doi = {10.1111/ecc.13502},
    journaltitle = {European Journal of Cancer Care},
    title = {Unmet supportive care needs of patients with rare cancer: A systematic review},
    issn = {0961-5423, 1365-2354},
    url = {https://onlinelibrary.wiley.com/doi/10.1111/ecc.13502},
    number = {6},
    date = {2021-11},
    journal = {European Journal of Cancer Care},
    shorttitle = {Unmet supportive care needs of patients with rare cancer},
    urldate = {2022-05-17},
    volume = {30},
    year = {2021},
    month = {aug},
    publisher = {Wiley},
}

@article{Heus2022,
    volume = {167},
    publisher = {Elsevier {BV}},
    qualityassured = {qualityAssured},
    shortjournal = {European Journal of Cancer},
    issn = {09598049},
    month = {may},
    shorttitle = {The gap between rare and common cancers still exists},
    year = {2022},
    doi = {10.1016/j.ejca.2022.03.001},
    readstatus = {read},
    pages = {103--111},
    author = {de Heus, Eline and Duijts, Saskia F.A. and van der Zwan, Jan Maarten and Kapiteijn, Ellen and Nieveen van Dijkum, Els J.M. and van Herpen, Carla M.L. and Merkx, Matthias A.W.},
    journaltitle = {European Journal of Cancer},
    date = {2022-05},
    langid = {english},
    urldate = {2022-05-17},
    title = {The gap between rare and common cancers still exists: Results from a population-based study in the Netherlands},
    journal = {European Journal of Cancer},
    ranking = {rank5},
    url = {https://linkinghub.elsevier.com/retrieve/pii/S0959804922001319},
}

@article{Hiripi2012,
    publisher = {Elsevier {BV}},
    doi = {10.1093/annonc/mdr131},
    month = {feb},
    number = {2},
    pages = {472--479},
    author = {E. Hiripi and A. Gondos and K. Emrich and B. Holleczek and A. Katalinic and S. Luttmann and E. Sirri and H. Brenner},
    relevance = {relevant},
    journal = {Annals of Oncology},
    volume = {23},
    title = {Survival from common and rare cancers in Germany in the early 21st century},
    year = {2012},
}

@article{hoes_patients_2022,
    url = {https://aacrjournals.org/clincancerres/article/28/7/1402/682217/Patients-with-Rare-Cancers-in-the-Drug-Rediscovery},
    file = {Full Text:C\:\\Users\\Kostadin\\Zotero\\storage\\6EXBCBJ6\\Hoes и др. - 2022 - Patients with Rare Cancers in the Drug Rediscovery.pdf:application/pdf},
    issn = {1078-0432, 1557-3265},
    title = {Patients with Rare Cancers in the Drug Rediscovery Protocol ({DRUP}) Benefit from Genomics-Guided Treatment},
    journaltitle = {Clinical Cancer Research},
    abstract = {Abstract

Purpose:
Patients with rare cancers (incidence less than 6 cases per 100,000 persons per year) commonly have less treatment opportunities and are understudied at the level of genomic targets. We hypothesized that patients with rare cancer benefit from approved anticancer drugs outside their label similar to common cancers.


Experimental Design:
In the Drug Rediscovery Protocol ({DRUP}), patients with therapy-refractory metastatic cancers harboring an actionable molecular profile are matched to {FDA}/European Medicines Agency–approved targeted therapy or immunotherapy. Patients are enrolled in parallel cohorts based on the histologic tumor type, molecular profile and study drug. Primary endpoint is clinical benefit (complete response, partial response, stable disease ≥ 16 weeks).


Results:
Of 1,145 submitted cases, 500 patients, including 164 patients with rare cancers, started one of the 25 available drugs and were evaluable for treatment outcome. The overall clinical benefit rate was 33\% in both the rare cancer and nonrare cancer subgroup. Inactivating alterations of {CDKN}2A and activating {BRAF} aberrations were overrepresented in patients with rare cancer compared with nonrare cancers, resulting in more matches to {CDK}4/6 inhibitors (14\% vs. 4\%; P ≤ 0.001) or {BRAF} inhibitors (9\% vs. 1\%; P ≤ 0.001). Patients with rare cancer treated with small-molecule inhibitors targeting {BRAF} experienced higher rates of clinical benefit (75\%) than the nonrare cancer subgroup.


Conclusions:
Comprehensive molecular testing in patients with rare cancers may identify treatment opportunities and clinical benefit similar to patients with common cancers. Our findings highlight the importance of access to broad molecular diagnostics to ensure equal treatment opportunities for all patients with cancer.},
    qualityassured = {qualityAssured},
    pages = {1402--1411},
    doi = {10.1158/1078-0432.CCR-21-3752},
    author = {Hoes, Louisa R. and van Berge Henegouwen, Jade M. and van der Wijngaart, Hanneke and Zeverijn, Laurien J. and van der Velden, Daphne L. and van de Haar, Joris and Roepman, Paul and de Leng, Wendy J. and Jansen, Anne M.L. and van Werkhoven, Erik and van der Noort, Vincent and Huitema, Alwin D.R. and Gort, Eelke H. and de Groot, Jan Willem B. and Kerver, Emile D. and de Groot, Derk Jan and Erdkamp, Frans and Beerepoot, Laurens V. and Hendriks, Mathijs P. and Smit, Egbert F. and van der Graaf, Winette T.A. and van Herpen, Carla M.L. and Labots, Mariette and Hoeben, Ann and Morreau, Hans and Lolkema, Martijn P. and Cuppen, Edwin and Gelderblom, Hans and Verheul, Henk M.W. and Voest, Emile E.},
    urldate = {2022-05-17},
    date = {2022-04-01},
    langid = {english},
    volume = {28},
    number = {7},
}

@article{Horick2016,
    title = {Physical and psychological health in rare cancer survivors},
    pages = {158--165},
    number = {1},
    year = {2016},
    doi = {10.1007/s11764-016-0573-0},
    journal = {Journal of Cancer Survivorship},
    publisher = {Springer Science and Business Media {LLC}},
    volume = {11},
    author = {Nora K. Horick and Adoma Manful and Jan Lowery and Susan Domchek and Patricia Moorman and Constance Griffin and Kala Visvanathan and Claudine Isaacs and Anita Y. Kinney and Dianne M. Finkelstein},
    month = {oct},
}

@article{Horick2018,
    month = {oct},
    author = {Nora K. Horick and Ariela Muzikansky and Hilda L. Gutierrez and Kristina L. Boyd and Dianne M. Finkelstein},
    volume = {12},
    publisher = {Springer Science and Business Media {LLC}},
    doi = {10.1007/s11764-018-0721-9},
    journal = {Journal of Cancer Survivorship},
    pages = {835--842},
    title = {Physical symptoms in long-term survivors of rare cancer},
    year = {2018},
    number = {6},
}

@article{IrmingerFinger2014,
    author = {Irmgard Irminger-Finger and Joanna Kargul and Geoff J. Laurent},
    volume = {53},
    publisher = {Elsevier {BV}},
    year = {2014},
    journal = {The International Journal of Biochemistry {\&}amp$\mathsemicolon$ Cell Biology},
    title = {Rare cancers: What we can learn from them},
    month = {aug},
    doi = {10.1016/j.biocel.2014.07.001},
    pages = {459--460},
}

@article{iskrov2018,
    url = {http://journal.raredis.org/index.php/RBLS/article/view/59},
    doi = {10.36865/2018.v9i4.59},
    journal = {Редки болести и лекарства сираци},
    shortjournal = {Редки болести и лекарства сираци},
    title = {Редките тумори – епидемиологични и общественоздравни аспекти},
    qualityassured = {qualityAssured},
    file = {Full Text:C\:/Users/Kostadin/Zotero/storage/P2VMSXEF/Искров и Стефанов - 2018 - Редките тумори – епидемиологични и общественоздрав.pdf:application/pdf;:./MEGAsync/phd/pdf/iskrov_rare_tumors.pdf:PDF},
    author = {Искров, Георги and Стефанов, Румен},
    issn = {1314-3581},
    month = {December},
    number = {4},
    urldate = {2022-05-17},
    abstract = {Редките злокачествени заболявания, наричани накратко редки тумори, са все по-популярна тема от научноизследователска, клинична и общественоздравна гледна точка. Злокачествените новообразувания сами по себе си представляват основен приоритет в съвременното здравеопазване и нозологична категория с огромна социална значимост. Следвайки обаче модела на редките болести, в научните среди все повече се говори за редките тумори. Съчетавайки медико-социалната парадигма на редките заболявания с клиничния профил на онкологията, редките тумори имат потенциал да бъдат самостоятелна област за действие с изключително висока степен на добавена стойност. 
Настоящата публикация има за цел да обобщи основните епидемиологични концепции по отношение на редките злокачествени заболявания и да обсъди мястото им в здравната политика.},
    pages = {9--13},
    year = {2018},
    volume = {9},
}

@article{iskrov_reglament_2020,
    author = {Искров, Георги and Стефанов, Румен},
    number = {3},
    url = {https://journal.raredis.org/index.php/RBLS/article/view/119},
    doi = {10.36865/2020.v11i3.119},
    title = {Регламент (ЕО) № 141/2000 за лекарствата сираци – 20 години по-късно},
    volume = {11},
    pages = {3-4},
    month = {Oct.},
    year = {2020},
    abstractnote = {&lt;p&gt;Тази година отбелязваме 20 години от влизане в сила на Регламент (ЕО) № 141/2000 на Европейския парламент и на Съвета от 16 декември 1999 г. за лекарствата сираци. Този нормативен акт определя критерии за обозначаването на определени лекарствени продукти като лекарства сираци за превенция, диагностика и лечение на редки състояния, както и осигурява стимули за тяхното проучване, разработване и предлагане на пазара. Въпреки че редките болести фигурират в някои по-ранни документи на европейското законодателство, този регламент е първият, който специално и ексклузивно засяга проблемите на хората с редки болести и техните семейства в Европа.&lt;/p&gt; &lt;p&gt;Двадесет години по-късно е време за равносметка. В този контекст, Европейската комисия проведе серия от обществени допитвания с различни заинтересовани страни, последвани от проучване на ефекта и резултатите от Регламент (ЕО) № 141/2000. Поводите за задоволство са много, но и идентифицираните проблеми не са никак малко. По най-важния въпрос обаче – адекватен достъп на пациентите с редки болести до терапия с лекарства сираци – успехът е частичен. Да, броят на лекарствата сираци, получили разрешение за пазарна употреба в ЕС, е значителен. Но в същото време се констатират огромни неравенства при достъпа до тях по страни членки. Съществена част от тези терапии остават недостъпни за пациентите от Източна Европа.&lt;/p&#38;gt;},
    file = {:iskrov_reglament_2020 - Регламент (ЕО) № 141_2000 За Лекарствата Сираци – 20 Години По Късно.pdf:PDF},
    journal = {Редки болести и лекарства сираци},
}

@article{iskrov_stefanov_2022,
    abstractnote = {&lt;p&gt;Традиционно, подходът при оценка на лекарствата сираци в Германия спада към т.нар. модел с фокус върху добавените здравни ползи. Това означава, че водещ критерий при вземане на решение за заплащане с публични средства е не разходната ефективност (както например е във Великобритания), а допълнителните здравни резултати на новата терапия спрямо алтернативата за сравнение. Привържениците на тази методология смятат за нейно основно предимство бързия достъп на пациентите до иновативни лечения, докато противниците й акцентират върху липсата на ефективен контрол върху разходите и цялостното бюджетно въздействие след това.&lt;/p&gt; &lt;p&gt;Оценката на лекарствата сираци в Германия се характеризира с друга особеност, характерна само за тази юрисдикция. Влезлият в сила през 2011 г. Закон за реформа на пазара на лекарствени продукти освобождава лекарствените терапии с орфанно обозначение от първоначална пълна оценка на здравните ползи. Вместо това, разрешението за пазарна употреба по централизираната процедура на Европейската лекарствена агенция служи като доказателство за наличие на добавени здравни ползи и съответно лекарствата сираци подлежат на съкратена процедура за ускорен достъп. Пълна оценка на тези здравни технологии е задължителна само когато определен лекарствен продукт надвиши 50 милиона евро обем на годишните продажби. В този случай вече, Институтът за качество и ефикасност в здравеопазването следва да извърши пълна оценка на здравните ползи, а Федералният съвместен комитет може да преразгледа решението си за достъп в светлината на представените доказателства. Десет години по-късно е време за равносметка.&lt;/p&#38;gt;},
    year = {2022},
    number = {4},
    url = {https://journal.raredis.org/index.php/RBLS/article/view/148},
    doi = {10.36865/2021.v12i4.148},
    author = {Искров, Георги and Стефанов, Румен},
    volume = {12},
    title = {Към нов подход при оценка на лекарствата сираци в Германия},
    month = {Feb},
    pages = {3-4},
    journal = {Редки болести и лекарства сираци},
}

@incollection{Jacobs2016,
    publisher = {Springer International Publishing},
    title = {Genetic Testing for Rare Cancer: The Wider Issues},
    year = {2016},
    booktitle = {Recent Results in Cancer Research},
    doi = {10.1007/978-3-319-29998-3_12},
    pages = {213--226},
    author = {Chris Jacobs and Gabriella Pichert},
}

@article{Jain2019,
    volume = {8},
    title = {Travel burden associated with rare cancers: The example of Merkel cell carcinoma},
    publisher = {Wiley},
    number = {5},
    doi = {10.1002/cam4.2085},
    author = {Rahul Jain and Joseph Menzin and Kristina Lachance and Patrick McBee and Hemant Phatak and Paul T. Nghiem},
    pages = {2580--2586},
    journal = {Cancer Medicine},
    year = {2019},
    month = {apr},
}

@article{James2015,
    journal = {Annals of Surgical Oncology},
    pages = {424--433},
    month = {oct},
    title = {The Incidence and Survival of Rare Cancers of the Thyroid, Parathyroid, Adrenal, and Pancreas},
    author = {Benjamin C. James and Briseis Aschebrook-Kilfoy and Nicole Cipriani and Edwin L. Kaplan and Peter Angelos and Raymon H. Grogan},
    number = {2},
    volume = {23},
    doi = {10.1245/s10434-015-4901-9},
    publisher = {Springer Science and Business Media {LLC}},
    year = {2015},
}

@article{jin_bayesian_2020,
    qualityassured = {qualityAssured},
    date = {2020-11-10},
    shortjournal = {Statistics in Medicine},
    doi = {10.1002/sim.8675},
    urldate = {2022-05-17},
    file = {:jin_bayesian_2020 - Bayesian Methods for the Analysis of Early‐phase Oncology Basket Trials with Information Borrowing across Cancer Types.pdf:PDF;Submitted Version:C\:/Users/Kostadin/Zotero/storage/3RFTJGTT/Jin и др. - 2020 - Bayesian methods for the analysis of early‐phase o.pdf:application/pdf},
    url = {https://onlinelibrary.wiley.com/doi/10.1002/sim.8675},
    number = {25},
    author = {Jin, Jin and Riviere, Marie‐Karelle and Luo, Xiaodong and Dong, Yingwen},
    issn = {0277-6715, 1097-0258},
    pages = {3459--3475},
    volume = {39},
    title = {Bayesian methods for the analysis of early‐phase oncology basket trials with information borrowing across cancer types},
    journaltitle = {Statistics in Medicine},
    langid = {english},
}

@article{Kaerlev2002,
    journal = {Journal of Occupational and Environmental Medicine},
    month = {jun},
    author = {Linda Kaerlev and Peter Stubbe Teglbjaerg and Svend Sabroe and Henrik A. Kolstad and Wolfgang Ahrens and Mikael Eriksson and Pascal Gu??nel and Lennart Hardell and Diane Cyr and Terri Ballard and Paola Zambon and Mar??a M. Morales Su??rez-Varela and Andreas Stang and Jorn Olsen},
    year = {2002},
    volume = {44},
    number = {6},
    doi = {10.1097/00043764-200206000-00012},
    pages = {516--522},
    title = {Occupational Risk Factors for Small Bowel Carcinoid Tumor: A European Population-Based Case-Control Study},
    publisher = {Ovid Technologies (Wolters Kluwer Health)},
}

@incollection{Kanitakis2009,
    author = {Jean Kanitakis},
    booktitle = {Skin Cancer after Organ Transplantation},
    relevance = {relevant},
    year = {2009},
    qualityassured = {qualityAssured},
    doi = {10.1007/978-0-387-78574-5_26},
    title = {Rare Skin Cancers},
    publisher = {Springer {US}},
    pages = {323--328},
}

@article{Kasper2020,
    month = {nov},
    title = {The challenge of drug approval in rare cancers},
    publisher = {Wiley},
    volume = {127},
    year = {2020},
    pages = {837--839},
    doi = {10.1002/cncr.33314},
    author = {Bernd Kasper},
    journal = {Cancer},
    number = {6},
}

@article{Katoh2019,
    journal = {Annals of Oncology},
    year = {2019},
    month = {oct},
    author = {Yoko Katoh and Akira Kawai and Taro Shibata and Yasushi Goto and Tatsuya Suzuki and Shintaro Iwata and Kan Yonemori and Wataru Munakata and Eriko Satomi and Akihiko Yoshida and Takuro Sakurai and Tomoko Takayama and Takahiro Higashi and Tosirou Nishida},
    publisher = {Elsevier {BV}},
    title = {Rare Cancer Center - All Activities for Rare Cancer Patients! -},
    volume = {30},
    doi = {10.1093/annonc/mdz341.002},
    pages = {vi51},
}

@article{keat_international_2013,
    qualityassured = {qualityAssured},
    doi = {10.1016/S1470-2045(12)70570-3},
    shortjournal = {The Lancet Oncology},
    pages = {109--110},
    langid = {english},
    issn = {14702045},
    date = {2013-02},
    title = {International Rare Cancers Initiative},
    url = {https://linkinghub.elsevier.com/retrieve/pii/S1470204512705703},
    number = {2},
    urldate = {2022-05-17},
    journaltitle = {The Lancet Oncology},
    volume = {14},
    author = {Keat, Nicola and Law, Kate and Seymour, Matthew and Welch, Jack and Trimble, Ted and Lascombe, Denis and Negrouk, Anastassia},
}

@article{Kendzia2022,
    publisher = {Oxford University Press ({OUP})},
    year = {2022},
    author = {Benjamin Kendzia and Linda Kaerlev and Wolfgang Ahrens and Franco Merletti and Mikael Eriksson and Pascal Gu{\'{e}}nel and Elsebeth Lynge and Altamiro Costa-Pereira and Maria Morales Su{\'{a}}rez-Varela and Karl-Heinz Jöckel and Andreas Stang and Thomas Behrens},
    journal = {American Journal of Epidemiology},
    month = {jul},
    title = {Lifetime Exposure to Welding Fumes and Risk of Some Rare Cancers},
    doi = {10.1093/aje/kwac123},
}

@article{KokkaliZervos2020,
    journal = {Annals of Oncology},
    year = {2020},
    doi = {10.1016/j.annonc.2020.08.1871},
    title = {1645P Real-world data on cabozantinib in advanced osteosarcoma and Ewing sarcoma - A study of the Hellenic Group of Sarcoma and Rare Cancers},
    month = {sep},
    author = {S. Kokkali-Zervos and A. Ardavanis and M. Panousieris and J. Duran and I. Boukovinas},
    volume = {31},
    pages = {S984},
    publisher = {Elsevier {BV}},
}

@article{komatsubara_promise_2016,
    langid = {english},
    pages = {136--138},
    title = {The promise and challenges of rare cancer research},
    volume = {17},
    issn = {14702045},
    url = {https://linkinghub.elsevier.com/retrieve/pii/S1470204515004854},
    shortjournal = {The Lancet Oncology},
    date = {2016-02},
    doi = {10.1016/S1470-2045(15)00485-4},
    urldate = {2022-05-17},
    number = {2},
    journaltitle = {The Lancet Oncology},
    author = {Komatsubara, Kimberly M and Carvajal, Richard D},
    qualityassured = {qualityAssured},
}

@article{Kondo2021,
    pages = {953--961},
    author = {Tadashi Kondo},
    publisher = {Wiley},
    volume = {112},
    title = {Current status and future outlook for patient-derived cancer models from a rare cancer research perspective},
    journal = {Cancer Science},
    doi = {10.1111/cas.14669},
    number = {3},
    month = {feb},
    year = {2021},
}

@article{Kondrashova201541,
    pages = {41 – 43},
    journal = {Cancer Forum},
    url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-84923626261&partnerID=40&md5=f8a65b131414b7289a69169be01efd6f},
    note = {Cited by: 1},
    number = {1},
    volume = {39},
    publication_stage = {Final},
    year = {2015},
    title = {Is genomics making rare cancers common and common cancers rare?},
    author = {Kondrashova, Olga and Waring, Paul},
}

@article{konsulova_2021,
    author = {Консулова, Ася and Йорданов, Ангел and Ел Шемери, Самър and Калчев, Калин and Стоева, Таня and Чаушева, Росица and Данчева, Живка and Спасов, Христо},
    number = {2},
    pages = {19-22},
    readstatus = {read},
    year = {2021},
    month = {Aug.},
    journal = {Редки болести и лекарства сираци},
    title = {Колко редки са редките онкологични болести?},
    url = {https://journal.raredis.org/index.php/RBLS/article/view/142},
    volume = {12},
    doi = {10.36865/2021.v12i2.142},
    abstractnote = {&lt;p&gt;Развитието на технологиите, молекулярната генетика и фармакологичната индустрия доведе до подобряване на лечебно-диагностичния процес в медицината. В онкологията през последните десетилетия много фатални в миналото диагнози се превърнаха в излечими или хронично протичащи болести. Това, обаче, не винаги е така при редките онкологични болести. Въпреки разминаването в различните определения за редки онкологични болести, епидемиологични данни сочат, че взети заедно, те съставляват над 20% от всички онкологични диагнози.&lt;/p&gt; &lt;p&gt;Обобщението на данните за тези редки нозологии в онкологията е ключово за тяхната по-добра диагноза, лечение. Известно е и, че тяхната регистрация е субоптимална, особено в страните от Източна Европа. Водещите проблеми в онкологията са свързани с диагнозата и откриването на туморите, за разлика от другите редки неонкологични болести и това влошава много клинични параметри. Вече има данни за удължаване на преживяемостта и подобряване на много клинични резултати при лечение и проследяване в специализирани центрове, поради което експертното поведение в специализирани центрове е силно препоръчително. Вече е изграден и концептуален модел за функциониращ специализиран център, към който да се стремят всички държави.&lt;/p&#38;gt;},
}

@article{Koo2020,
    journal = {Cancer Epidemiology},
    doi = {10.1016/j.canep.2020.101845},
    year = {2020},
    month = {dec},
    title = {The prevalence of chronic conditions in patients diagnosed with one of 29 common and rarer cancers: A cross-sectional study using primary care data},
    pages = {101845},
    author = {Minjoung Monica Koo and Ruth Swann and Sean McPhail and Gary A. Abel and Cristina Renzi and Greg P. Rubin and Georgios Lyratzopoulos},
    publisher = {Elsevier {BV}},
    volume = {69},
}

@article{Koyyala2020,
    volume = {41},
    pages = {801--803},
    doi = {10.4103/ijmpo.ijmpo_234_20},
    journal = {Indian Journal of Medical and Paediatric Oncology},
    publisher = {Georg Thieme Verlag {KG}},
    author = {Venkata Pradeep Babu Koyyala and Padmaj Kulkarni},
    title = {Immunotherapy in Rare Cancers},
    year = {2020},
    number = {06},
    month = {nov},
}

@article{Krendyukov2021,
    doi = {10.3389/fonc.2021.636561},
    readstatus = {read},
    volume = {11},
    month = {mar},
    year = {2021},
    journal = {Frontiers in Oncology},
    publisher = {Frontiers Media {SA}},
    title = {Value of Adaptive Trials and Surrogate Endpoints for Clinical Decision-Making in Rare Cancers},
    author = {Andriy Krendyukov and Sanjay Singhvi and Markus Zabransky},
}

@article{Kuenzel2017,
    year = {2017},
    publisher = {Springer Science and Business Media {LLC}},
    volume = {33},
    number = {5},
    pages = {960--966},
    journal = {Journal of Cancer Education},
    doi = {10.1007/s13187-017-1173-z},
    title = {Evaluation of the Quality of Online Information for Patients with Rare Cancers: Thyroid Cancer},
    month = {jan},
    author = {Ulrike Kuenzel and Tabea Monga Sindeu and Sarah Schroth and Jutta Huebner and Natalie Herth},
}

@article{Kwak2020,
    year = {2020},
    month = {feb},
    title = {Acknowledging the Unsung Role of the Cancer Registry in Rare Cancers},
    author = {Jung-Myun Kwak},
    volume = {36},
    publisher = {Korean Society of Coloproctology},
    readstatus = {read},
    pages = {1--2},
    doi = {10.3393/ac.2020.02.11},
    journal = {Annals of Coloproctology},
    number = {1},
}

@article{L.Kaerlev2001,
    journal = {Scandinavian Journal of Gastroenterology},
    month = {jan},
    number = {6},
    volume = {36},
    pages = {641--646},
    year = {2001},
    author = {L. Kaerlev, P. Stubbe Teglbjaerg, S},
    doi = {10.1080/00365520118247},
    publisher = {Informa {UK} Limited},
    title = {Medical Risk Factors for Small-Bowel Adenocarcinoma with Focus on Crohn Disease: A European Population-based Case-Control Study},
}

@article{Lacour2010,
    doi = {10.1097/cej.0b013e32833876c0},
    journal = {European Journal of Cancer Prevention},
    month = {may},
    title = {Incidence of childhood cancer in France: National Children Cancer Registries, 2000{\textendash}2004},
    author = {Brigitte Lacour and Aur{\'{e}}lie Guyot-Goubin and Sandra Guissou and St{\'{e}}phanie Bellec and Emmanuel D{\'{e}}sandes and Jacqueline Clavel},
    number = {3},
    volume = {19},
    pages = {173--181},
    year = {2010},
    publisher = {Ovid Technologies (Wolters Kluwer Health)},
}

@article{Lancaster2005,
    title = {Rare cancer cell analyzer for whole blood applications: Microcytometer cell counting and sorting subcircuits},
    author = {C. Lancaster and M. Kokoris and M. Nabavi and J. Clemmens and P. Maloney and J. Capadanno and J. Gerdes and C.F. Battrell},
    doi = {10.1016/j.ymeth.2005.07.003},
    volume = {37},
    year = {2005},
    pages = {120--127},
    number = {1},
    publisher = {Elsevier {BV}},
    month = {sep},
    journal = {Methods},
}

@article{Larsen2019,
    volume = {103},
    publisher = {Elsevier {BV}},
    number = {5},
    title = {Radiation Therapy in Resectable Intrathoracic Sarcomas. A Rare Cancer Network Study},
    year = {2019},
    month = {apr},
    author = {Francisco Larsen and Mario Terlizzi and Virginia Linacre and Paul Sargos and Francisco Suarez and Youlia Kirova and Paul Van Houtte and Delphine Lerouge and Thomas Zilli and Claudio V. Sole},
    doi = {10.1016/j.ijrobp.2018.12.022},
    pages = {1175--1181},
    journal = {International Journal of Radiation Oncology{\ast}Biology{\ast}Physics},
}

@article{Ledford2017,
    month = {may},
    number = {7654},
    pages = {278--278},
    publisher = {Springer Science and Business Media {LLC}},
    year = {2017},
    doi = {10.1038/nature.2017.21975},
    author = {Heidi Ledford},
    volume = {545},
    title = {Century-old tumours offer rare cancer clues},
    journal = {Nature},
}

@article{Limon2014,
    month = {aug},
    title = {Rare cancers},
    doi = {10.1016/j.biocel.2014.06.001},
    journal = {The International Journal of Biochemistry {\&}amp$\mathsemicolon$ Cell Biology},
    publisher = {Elsevier {BV}},
    year = {2014},
    pages = {461},
    author = {Janusz Limon and Markku Miettinen and Jerzy Lasota},
    volume = {53},
}

@article{Liontos2020,
    author = {Michalis Liontos and Evangelos Karamitrousis and Nikolaos Tsoukalas and Ioannis Boukovinas},
    publisher = {Walter de Gruyter {GmbH}},
    pages = {1--2},
    doi = {10.2478/fco-2019-0024},
    month = {dec},
    number = {3},
    volume = {11},
    year = {2020},
    journal = {Forum of Clinical Oncology},
    title = {Rare cancers are common: time to act},
}

@article{Loggers2014,
    doi = {10.4081/rt.2014.5281},
    year = {2014},
    journal = {Rare Tumors},
    title = {The End-of-Life Experience of Patients with Rare Cancers and their Caregivers},
    month = {mar},
    author = {Elizabeth Trice Loggers and Holly G. Prigerson},
    pages = {24--27},
    volume = {6},
    number = {1},
    publisher = {{SAGE} Publications},
}

@article{Longabaugh2017,
    journal = {Surgical Oncology Clinics of North America},
    doi = {10.1016/j.soc.2016.07.014},
    year = {2017},
    author = {Michele Longabaugh},
    number = {1},
    month = {jan},
    pages = {1--7},
    publisher = {Elsevier {BV}},
    title = {Patient Perspective and Personal Journey of Treating a {\textquotedblleft}Rare Cancer{\textquotedblright}},
    volume = {26},
}

@article{Louveau2020,
    year = {2020},
    publisher = {Elsevier {BV}},
    title = {The key role of oncopharmacology in therapeutic management, from common to rare cancers: A literature review},
    month = {apr},
    doi = {10.1016/j.therap.2020.02.010},
    author = {Baptiste Louveau and Fan{\'{e}}lie Jouenne and Florentia Kaguelidou and Alexandra Landras and Lauriane Goldwirt and Samia Mourah},
    number = {2},
    volume = {75},
    pages = {183--193},
    readstatus = {read},
    journal = {Therapies},
}

@article{Lu2021,
    pages = {20},
    journal = {New Scientist},
    month = {jan},
    publisher = {Elsevier {BV}},
    author = {Donna Lu},
    title = {Rare cancers jumped from mother to child},
    year = {2021},
    number = {3317},
    volume = {249},
    doi = {10.1016/s0262-4079(21)00050-6},
}

@article{Lukic2018,
    pages = {287--302},
    doi = {10.1007/s10654-018-0369-9},
    month = {feb},
    author = {Marko Lukic and Lena Maria Nilsson and Guri Skeie and Bernt Lindahl and Tonje Braaten},
    journal = {European Journal of Epidemiology},
    volume = {33},
    year = {2018},
    title = {Coffee consumption and risk of rare cancers in Scandinavian countries},
    number = {3},
    publisher = {Springer Science and Business Media {LLC}},
}

@article{Lynge2005,
    pages = {601--612},
    doi = {10.1016/j.ejca.2004.12.016},
    readstatus = {read},
    volume = {41},
    author = {Elsebeth Lynge and Noemia Afonso and Linda Kaerlev and J{\o}rn Olsen and Svend Sabroe and Wolfgang Ahrens and Mikael Eriksson and Pascal Gu{\'{e}}nel and Franco Merletti and Aivars Stengrevics and Maria Suarez-Varela and Altamiro Costa-Pererra and Mogens Vyberg},
    number = {4},
    title = {European multi-centre case{\textendash}control study on risk factors for rare cancers of unknown aetiology},
    journal = {European Journal of Cancer},
    year = {2005},
    publisher = {Elsevier {BV}},
    month = {mar},
}

@article{Lynge2020,
    month = {jul},
    title = {Rare cancers of unknown etiology: lessons learned from a European multi-center case{\textendash}control study},
    journal = {European Journal of Epidemiology},
    publisher = {Springer Science and Business Media {LLC}},
    pages = {937--948},
    doi = {10.1007/s10654-020-00663-y},
    number = {10},
    author = {Elsebeth Lynge and Linda Kaerlev and J{\o}rn Olsen and Svend Sabroe and Noemia Afonso and Wolfgang Ahrens and Mikael Eriksson and Franco Merletti and Maria Morales-Suarez-Varelas and Aivars Stengrevics and Pascal Gu{\'{e}}nel},
    volume = {35},
    year = {2020},
}

@article{Majima2018,
    volume = {29},
    journal = {Annals of Oncology},
    doi = {10.1093/annonc/mdy386},
    publisher = {Elsevier {BV}},
    month = {oct},
    year = {2018},
    pages = {vii36},
    author = {Yoshiyuki Majima},
    title = {Patients expectation for drug discovery development targeting rare cancers},
}

@article{mariaoccu2004,
    abstract = {Mycosis fungoides (MF) is a rare disease with an unknown etiology. Its distribution suggests that occupational exposures may play a role. In the present study, we searched for occupational factors associated with MF. A European multicenter case-control study on seven rare cancers, including MF, was conducted from 1995 to 1997. Patients between 35 and 69 years of age diagnosed with MF (n = 134) were identified and their diagnoses were checked by a reference pathologist who classified 83 cases as definitive, 35 cases as possible, and 16 cases as not histologically verified Of the 118 histologically verified cases, 104 were interviewed, of which 76 were definitive cases. As controls, we selected population controls and colon cancer controls to serve all seven case groups. Altogether, 833 colon cancer controls and 2071 population controls were interviewed. The response rate was 91.5% for cases (76 of the 83 definitive cases), and 66.6% for controls. A high risk of MF for men was observed in the industries of other non-metallic mineral products (Odds Ratio [OR] 5.3, 95% confidence interval [CI] = 1.7-16.2) and of wholesale trade (OR 3.6, 95% CI = 1.3-10.5). A high risk was found for female employees in the sector of pulp paper manufacture (OR 14.4, 95% CI = 2.2-95.1). The male occupations with the highest risks were glass formers, potters, and ceramics workers (OR 17.9, 95% CI = 5.4-59.4) and technical salesmen (OR 8.6, 95% CI = 2.4-30.8). For women, the occupations associated with the highest risks were government executives (OR 4.8, 95% CI = 1.0-22.6) and railway and road vehicles loaders (OR 3.9, 95% CI = 1.0-14.0). The results suggest that some occupational factors are associated with MF. Working as glass formers, pottery, and ceramics workers carried the highest risk, and these findings deserve further attention and replication. Females working in the paper and pulp industries may also be exposed to carcinogens of relevance to MF.},
    number = {3},
    title = {Occupational Risk Factors for Mycosis Fungoides: A European Multicenter Case-Control Study},
    urldate = {2022-08-24},
    author = {Maria M. Morales-Suárez-Varela and Jorn Olsen and Preben Johansen and Linda Kaerlev and Pascal Guénel and Patrick Arveux and Gun Wingren and Lennart Hardell and Wolfgang Ahrens and Andreas Stang and Agustin Llopis and Franco Merletti and Juan Jose Aurrekoetxea and Giovanna Masala},
    issn = {10762752, 15365948},
    volume = {46},
    year = {2004},
    journal = {Journal of Occupational and Environmental Medicine},
    publisher = {Lippincott Williams & Wilkins},
    url = {http://www.jstor.org/stable/44996559},
    pages = {205--211},
}

@article{Marques2021,
    readstatus = {read},
    volume = {32},
    publisher = {Elsevier {BV}},
    author = {Carina Marques and Charlotte Roberts and Vitor M.J. Matos and Jane E. Buikstra},
    doi = {10.1016/j.ijpp.2020.12.005},
    title = {Cancers as rare diseases: Terminological, theoretical, and methodological biases},
    year = {2021},
    month = {mar},
    journal = {International Journal of Paleopathology},
    pages = {111--122},
}

@article{Marty2008,
    number = {6},
    pages = {360--362},
    doi = {10.1007/s10269-008-0894-3},
    month = {jun},
    title = {Cancers rares : des entit{\'{e}}s diff{\'{e}}rentes, des probl{\'{e}}matiques communes},
    journal = {Oncologie},
    publisher = {Computers, Materials and Continua (Tech Science Press)},
    volume = {10},
    year = {2008},
    author = {M. Marty and N. Rheims},
}

@article{MathoulinPelissier2019,
    journaltitle = {European Journal of Surgical Oncology},
    year = {2019},
    urldate = {2022-05-17},
    number = {1},
    volume = {45},
    qualityassured = {qualityAssured},
    doi = {10.1016/j.ejso.2018.02.015},
    month = {jan},
    file = {Submitted Version:C\:\\Users\\Kostadin\\Zotero\\storage\\4EIJ9SI6\\Mathoulin-Pélissier и Pritchard-Jones - 2019 - Evidence-based data and rare cancers The need for.pdf:application/pdf},
    publisher = {Elsevier {BV}},
    langid = {english},
    pages = {22--30},
    date = {2019-01},
    shorttitle = {Evidence-based data and rare cancers},
    url = {https://linkinghub.elsevier.com/retrieve/pii/S0748798318306784},
    journal = {European Journal of Surgical Oncology},
    shortjournal = {European Journal of Surgical Oncology},
    issn = {07487983},
    title = {Evidence-based data and rare cancers: The need for a new methodological approach in research and investigation},
    author = {Mathoulin-Pélissier, S. and Pritchard-Jones, K.},
}

@article{matsuda_rare_2020,
    volume = {67},
    journaltitle = {Cancer Epidemiology},
    urldate = {2022-05-17},
    shortjournal = {Cancer Epidemiology},
    issn = {18777821},
    langid = {english},
    date = {2020-08},
    doi = {10.1016/j.canep.2020.101702},
    qualityassured = {qualityAssured},
    title = {Rare cancers are not rare in Asia as well: The rare cancer burden in East Asia},
    author = {Matsuda, Tomohiro and Won, Young-Joo and Chun-ju Chiang, {RuRu} and Lim, Jiwon and Saika, Kumiko and Fukui, Keisuke and Lee, Wen-Chung and Botta, Laura and Bernasconi, Alice and Trama, Annalisa},
    shorttitle = {Rare cancers are not rare in Asia as well},
    pages = {101702},
    url = {https://linkinghub.elsevier.com/retrieve/pii/S1877782120300369},
}

@article{mattiuzzi2019,
    journal = {Journal of Epidemiology and Global Health},
    doi = {10.2991/jegh.k.191008.001},
    langid = {en},
    author = {Mattiuzzi, Camilla and Lippi, Giuseppe},
    date = {2019},
    title = {Current Cancer Epidemiology},
    url = {http://dx.doi.org/10.2991/jegh.k.191008.001},
    volume = {9},
    number = {4},
    pages = {217},
    year = {2019},
}

@article{Mayor2016,
    journal = {{BMJ}},
    month = {feb},
    pages = {i1198},
    doi = {10.1136/bmj.i1198},
    publisher = {{BMJ}},
    title = {A quarter of patients with rarer cancers see {GPs} several times before referral},
    year = {2016},
    author = {Susan Mayor},
}

@article{Merks2011,
    author = {Johannes H. M. Merks and Ines B. Brecht},
    pages = {69--94},
    title = {Genetic Predisposition and Genetic Susceptibility},
    month = {oct},
    publisher = {Springer Berlin Heidelberg},
    doi = {10.1007/978-3-642-04197-6_6},
    booktitle = {Rare Tumors In Children and Adolescents},
    year = {2011},
}

@article{Minicozzi2017,
    doi = {10.1016/j.ejca.2017.07.015},
    journal = {European Journal of Cancer},
    year = {2017},
    title = {Quality analysis of population-based information on cancer stage at diagnosis across Europe, with presentation of stage-specific cancer survival estimates: A~{EUROCARE}-5 study},
    pages = {335--353},
    publisher = {Elsevier {BV}},
    month = {oct},
    author = {Pamela Minicozzi and Kaire Innos and Maria-Jos{\'{e}} S{\'{a}}nchez and Annalisa Trama and Paul M. Walsh and Rafael Marcos-Gragera and Nadya Dimitrova and Laura Botta and Otto Visser and Silvia Rossi and Andrea Tavilla and Milena Sant and M. Hackl and N. Zielonke and E. Van Eycken and K. Henau and Z. Valerianova and N. Dimitrova and M. Sekerija and L. Du{\v{s}}ek and M. Zvolsk{\'{y}} and M. Mägi and T. Aareleid and N. Malila and K. Seppä and A.M. Bouvier and J. Faivre and N. Bossard and Z. Uhry and M. Colonna and R. Stabenow and S. Luttmann and A. Eberle and H. Brenner and A. Nennecke and J. Engel and G. Schubert-Fritschle and J. Heidrich and B. Holleczek and A. Katalinic and K. Clough-Gorr and G. Mazzoleni and A. Bulatko and C. Buzzoni and A. Giacomin and S. Ferretti and A. Barchielli and A. Caldarella and G. Gatta and M. Sant and H. Amash and C. Amati and P. Baili and F. Berrino and S. Bonfarnuzzo and L. Botta and R. Capocaccia and F. Di Salvo and R. Foschi and C. Margutti and E. Meneghini and P. Minicozzi and A. Trama and D. Serraino and L. Dal Maso and R. De Angelis and M. Caldora and E. Carrani and S. Francisci and A. Knijn and S. Mallone and D. Pierannunzio and P. Roazzi and S. Rossi and M. Santaquilani and A. Tavilla and F. Pannozzo and M. Natali and R.A. Filiberti and E. Marani and M. Autelitano and G. Spagnoli and C. Cirilli and M. Fusco and M.F. Vitale and A. Traina and R. Staiti and F. Vitale and R. Cusimano and M. Michiara and R. Tumino and F. Falcini and A.L. Caiazzo and S. Maspero and A.C. Fanetti and R. Zanetti and S. Rosso and M. Rugge and S. Tognazzo and S. Pildava and G. Smailyte and T.B. Johannesen and J. Rachtan and S. G{\'{o}}{\'{z}}d{\'{z}} and R. M{\k{e}}{\.{z}}yk and J. B{\l}aszczyk and K. K{\k{e}}pska and M. Bielska-Lasota and G. Forjaz de Lacerda and M.J. Bento and L. Antunes and A. Miranda and A. Mayer-da-Silva and C. Safaei Diba and M. Primic-Zakelj and E. Almar and A. Mateos and A. Lopez de Munain and N. Larra{\~{n}}aga and A. Torrella-Ramos and J.M. D{\'{\i}}az Garc{\'{\i}}a and R. Jimenez-Chillaron and R. Marcos-Gragera and L. Vilardell and C. Moreno-Iribas and E. Ardanaz and M. Lambe and M. Mousavi and C. Bouchardy and M. Usel and S.M. Ess and H. Frick and M. Lorez and S.M. Ess and C. Herrmann and A. Bordoni and A. Spitale and I. Konzelmann and O. Visser and R. Damhuis and R. Otter and M. Coleman and C. Allemani and B. Rachet and J. Rashbass and J. Broggio and J. Verne and A. Gavin and D. Fitzpatrick and D.W. Huws and C. White},
    volume = {84},
}

@article{Missaoui2018,
    doi = {10.1016/j.prp.2018.03.004},
    pages = {498--506},
    number = {4},
    publisher = {Elsevier {BV}},
    title = {{HPV} infection and p16 {INK}4A and {TP}53 expression in rare cancers of the uterine cervix},
    volume = {214},
    month = {apr},
    year = {2018},
    author = {Nabiha Missaoui and Sarra Mestiri and Ahlem Bdioui and Thouraya Zahmoul and Hajer Hamchi and Moncef Mokni and Sihem Hmissa},
    journal = {Pathology - Research and Practice},
}

@article{Morfouace2020,
    doi = {10.1016/s0959-8049(20)31155-2},
    title = {Arcagen: Molecular profiling of rare cancer patients {\textendash} analysis of the pilot study (87 patients)},
    journal = {European Journal of Cancer},
    author = {M. Morfouace and I. Ray-Coquard and N. Girard and A. Stevovic and I. Treilleux and P. Meeus and S. Aust and A. Floquet and S. Croce and M. Seckl and J. Gietema and M. Caplin and C. delaFouchardiere and L. Licitra and H. Kapiteijn and S. Piperno Neumann and A. Idbaih and J.Y. Blay},
    year = {2020},
    pages = {S32},
    publisher = {Elsevier {BV}},
    volume = {138},
    month = {oct},
}

@article{Munoz2012,
    pages = {631--642},
    url = {http://www.nature.com/articles/nrclinonc.2012.160},
    issn = {1759-4774, 1759-4782},
    publisher = {Springer Science and Business Media {LLC}},
    date = {2012-11},
    qualityassured = {qualityAssured},
    shortjournal = {Nat Rev Clin Oncol},
    number = {11},
    journaltitle = {Nature Reviews Clinical Oncology},
    year = {2012},
    journal = {Nature Reviews Clinical Oncology},
    urldate = {2022-05-17},
    volume = {9},
    month = {sep},
    langid = {english},
    title = {Targeted therapy in rare cancers—adopting the orphans},
    doi = {10.1038/nrclinonc.2012.160},
    author = {Munoz, Javier and Kurzrock, Razelle},
}

@article{naing2020phase,
    doi = {10.1136/jitc-2019-000347},
    year = {2020},
    journal = {Journal for immunotherapy of cancer},
    number = {1},
    author = {Naing, Aung and Meric-Bernstam, Funda and Stephen, Bettzy and Karp, Daniel D and Hajjar, Joud and Ahnert, Jordi Rodon and Piha-Paul, Sarina A and Colen, Rivka R and Jimenez, Camilo and Raghav, Kanwal P and others},
    title = {Phase 2 study of pembrolizumab in patients with advanced rare cancers},
    volume = {8},
    publisher = {BMJ Publishing Group},
}

@article{Nicolazzo2018,
    doi = {10.1155/2018/9718585},
    year = {2018},
    journal = {Analytical Cellular Pathology},
    title = {Liquid Biopsy in Rare Cancers: Lessons from Hemangiopericytoma},
    author = {Chiara Nicolazzo and Luciano Colangelo and Alessandro Corsi and Guido Carpino and Angela Gradilone and Chiara Sonato and Cristina Raimondi and Eugenio Gaudio and Paola Gazzaniga and Walter Gianni},
    pages = {1--4},
    publisher = {Hindawi Limited},
    volume = {2018},
}

@misc{nihHomeGenetic,
    url = {\url{https://rarediseases.info.nih.gov/about}},
    title = {Genetic and Rare Diseases Information Center},
    note = {(Accessed on 08/25/2022)},
    readstatus = {read},
}

@article{Noda2018,
    year = {2018},
    author = {S. Noda and K. Yonemori and N. Shirakawa and H.S. Okuma and T. Shimizu and A. Hirakawa and T. Shibata and T. Sukigara and N. Okita and A. Kawai and N. Yamamoto and K. Nakamura and H. Mano and T. Nishida and Y. Fujiwara},
    publisher = {Elsevier {BV}},
    volume = {29},
    journal = {Annals of Oncology},
    month = {oct},
    doi = {10.1093/annonc/mdy279.436},
    pages = {viii148},
    title = {{MASTER} {KEY} project: A basket/umbrella trial for rare cancers in Japan},
}

@article{OConnor2020,
    month = {sep},
    volume = {8},
    journal = {Expert Opinion on Orphan Drugs},
    author = {Daniel J O'Connor},
    pages = {309--310},
    number = {9},
    doi = {10.1080/21678707.2020.1821529},
    title = {Rare cancers, the continued agenda for progress {\textendash} editor's special foreword},
    year = {2020},
    publisher = {Informa {UK} Limited},
}

@article{Okuma2022,
    author = {Hitomi Okuma},
    volume = {33},
    doi = {10.1016/j.annonc.2022.05.486},
    journal = {Annals of Oncology},
    year = {2022},
    publisher = {Elsevier {BV}},
    title = {{SY}24-1 {MASTER} {KEY} Project: A platform study for rare cancers in Japan and Asia},
    month = {jul},
    readstatus = {read},
    pages = {S448},
}

@article{Olischlaeger2022,
    month = {jul},
    doi = {10.1080/09638288.2022.2099589},
    publisher = {Informa {UK} Limited},
    author = {Daphne L. T. Olischläger and Li Xiang Y. den Boer and Eline de Heus and Linda Brom and Desiree J. S. Dona and Heinz-Josef Klümpen and Christina M. Stapelfeldt and Saskia F. A. Duijts},
    title = {Rare cancer and return to work: experiences and needs of patients and (health care) professionals},
    year = {2022},
    journal = {Disability and Rehabilitation},
    pages = {1--12},
    readstatus = {read},
}

@article{Olver2015,
    doi = {10.5694/mja15.00974},
    number = {10},
    author = {Ian N Olver},
    year = {2015},
    journal = {Medical Journal of Australia},
    volume = {203},
    pages = {386--386},
    publisher = {{AMPCo}},
    month = {nov},
    title = {Reassessing rare cancers},
}

@article{Onega2022,
    author = {Tracy Onega and Jennifer Alford-Teaster and Chris Leggett and Andrew Loehrer and Julie E. Weiss and Erika L. Moen and Catherine C. Pollack, and Fahui Wang},
    month = {jul},
    doi = {10.1111/jrh.12693},
    journal = {The Journal of Rural Health},
    title = {The interaction of rurality and rare cancers for travel time to cancer care},
    publisher = {Wiley},
    year = {2022},
    readstatus = {read},
}

@article{Pappo2015,
    shortjournal = {{JCO}},
    journal = {Journal of Clinical Oncology},
    month = {sep},
    pages = {3047--3054},
    qualityassured = {qualityAssured},
    author = {Pappo, Alberto S. and Furman, Wayne L. and Schultz, Kris A. and Ferrari, Andrea and Helman, Lee and Krailo, Mark D.},
    date = {2015-09-20},
    publisher = {American Society of Clinical Oncology ({ASCO})},
    shorttitle = {Rare Tumors in Children},
    doi = {10.1200/JCO.2014.59.3632},
    number = {27},
    issn = {0732-183X, 1527-7755},
    abstract = {Rare pediatric tumors account for approximately 10\% of all childhood cancers, which in themselves are a rare entity. The diverse histologies and clinical behaviors of rare pediatric tumors pose challenges to the investigation of their biologic and clinical features. National and international cooperative groups such as the Rare Tumor Committee of the Children's Oncology Group, Rare Tumors in Pediatric Age Project, and European Cooperative Study Group for Pediatric Rare Tumors have developed several initiatives to advance knowledge about rare pediatric cancers. However, these programs have been only partially effective, necessitating the development of alternative mechanisms to study these challenging diseases. In this article, we review the current national and international collaborative strategies to study rare pediatric cancers and alternative methods under exploration to enhance those efforts, such as independent registries and disease-specific, National Cancer Institute–sponsored clinics.},
    title = {Rare Tumors in Children: Progress Through Collaboration},
    urldate = {2022-05-17},
    url = {https://ascopubs.org/doi/10.1200/JCO.2014.59.3632},
    volume = {33},
    langid = {english},
    year = {2015},
    journaltitle = {Journal of Clinical Oncology},
}

@article{Pasquier2015,
    number = {4},
    month = {jul},
    pages = {904--910},
    author = {David Pasquier and Brandon Barney and Santhanam Sundar and Philip Poortmans and Salvador Villa and Haitam Nasrallah and Noureddine Boujelbene and Pirus Ghadjar and Yasmin Lassen-Ramshad and El{\.{z}}bieta Senkus and Andrew Oar and Martine Roelandts and Maurizio Amichetti and Hansjoerg Vees and Thomas Zilli and Mahmut Ozsahin},
    title = {Small Cell Carcinoma of the Urinary Bladder: A Retrospective, Multicenter Rare Cancer Network Study of 107 Patients},
    year = {2015},
    publisher = {Elsevier {BV}},
    doi = {10.1016/j.ijrobp.2015.03.019},
    journal = {International Journal of Radiation Oncology{\ast}Biology{\ast}Physics},
    volume = {92},
}

@article{Petrov2022,
    volume = {11},
    journal = {{eLife}},
    doi = {10.7554/elife.74010},
    publisher = {{eLife} Sciences Publications, Ltd},
    readstatus = {skimmed},
    month = {may},
    author = {Iurii Petrov and Andrey Alexeyenko},
    year = {2022},
    title = {Individualized discovery of rare cancer drivers in global network context},
}

@article{Pierotti2009,
    journal = {Molecular Oncology},
    author = {Marco A. Pierotti and Tiziana Negri and Elena Tamborini and Federica Perrone and Sabrina Pricl and Silvana Pilotti},
    month = {oct},
    readstatus = {read},
    year = {2009},
    number = {1},
    title = {Targeted Therapies: The Rare Cancer Paradigm},
    volume = {4},
    doi = {10.1016/j.molonc.2009.10.003},
    publisher = {Wiley},
    pages = {19--37},
}

@article{Pillai2017,
    journal = {Indian Journal of Medical Research},
    publisher = {Medknow},
    volume = {145},
    author = {RaveendranK Pillai and K Jayasree},
    doi = {10.4103/ijmr.ijmr_915_14},
    year = {2017},
    pages = {17},
    title = {Rare cancers: Challenges and issues},
    number = {1},
}

@article{Porta2012,
    volume = {62},
    publisher = {Elsevier {BV}},
    pages = {1020--1021},
    author = {Camillo Porta},
    doi = {10.1016/j.eururo.2012.07.035},
    journal = {European Urology},
    number = {6},
    title = {How to Identify Active Novel Agents in Rare Cancers and then Make Them Available: A Need for a Paradigm Shift},
    year = {2012},
    month = {dec},
}

@article{Prades2020,
    journal = {Journal of Cancer Policy},
    year = {2020},
    pages = {100222},
    publisher = {Elsevier {BV}},
    doi = {10.1016/j.jcpo.2020.100222},
    volume = {24},
    title = {Priorities on rare cancers' policy in National Cancer Control Plans ({NCCPs}): A review conducted within the framework of {EU}-{JARC} Joint-Action},
    author = {Joan Prades and Ariane Weinman and Yann Le Cam and Annalisa Trama and Anna Maria Frezza and Josep M. Borras},
    month = {jun},
}

@article{Prasad2015,
    doi = {10.1016/j.ejca.2015.04.015},
    pages = {1355--1357},
    publisher = {Elsevier {BV}},
    journal = {European Journal of Cancer},
    volume = {51},
    year = {2015},
    author = {Vinay Prasad and Andrew Oseran},
    month = {jul},
    number = {11},
    title = {Do we need randomised trials for rare cancers?},
}

@article{PritchardJones2006,
    number = {13},
    publisher = {Elsevier {BV}},
    month = {sep},
    doi = {10.1016/j.ejca.2006.06.006},
    author = {K. Pritchard-Jones and P. Kaatsch and E. Steliarova-Foucher and C.A. Stiller and J.W.W. Coebergh},
    journal = {European Journal of Cancer},
    pages = {2183--2190},
    volume = {42},
    year = {2006},
    title = {Cancer in children and adolescents in Europe: Developments over 20 years and future challenges},
}

@article{Pui2016,
    volume = {17},
    year = {2016},
    month = {feb},
    number = {2},
    publisher = {Elsevier {BV}},
    journal = {The Lancet Oncology},
    author = {Ching-Hon Pui and Alberto Pappo and Amar Gajjar and James R Downing},
    pages = {138--139},
    title = {Redefining {\textquotedblleft}rare{\textquotedblright} in paediatric cancers},
    doi = {10.1016/s1470-2045(15)00538-0},
}

@article{raghavan_structured_2013,
    title = {A structured approach to uncommon cancers: what should a clinician do?},
    number = {12},
    url = {https://linkinghub.elsevier.com/retrieve/pii/S0923753419367523},
    langid = {english},
    journaltitle = {Annals of Oncology},
    doi = {10.1093/annonc/mdt432},
    volume = {24},
    qualityassured = {qualityAssured},
    urldate = {2022-05-17},
    pages = {2932--2934},
    shortjournal = {Annals of Oncology},
    date = {2013-12},
    shorttitle = {A structured approach to uncommon cancers},
    issn = {09237534},
    author = {Raghavan, D.},
    file = {Full Text:C\:\\Users\\Kostadin\\Zotero\\storage\\DXTQMCHK\\Raghavan - 2013 - A structured approach to uncommon cancers what sh.pdf:application/pdf},
}

@misc{rare_agenda2030,
    journal = {Rare Cancers Europe},
    title = {Rare cancer agenda 2030},
    month = {Mar},
    author = {Pozzi, Mariya},
    publisher = {European Society for Medical Oncology (ESMO)},
    year = {2022},
    url = {https://www.rarecancerseurope.org/rare-cancers-in-europe/rare-cancer-agenda-2030},
}

@article{Ravindran2016,
    pages = {251--252},
    doi = {10.1080/10428194.2016.1193854},
    month = {jun},
    volume = {58},
    year = {2016},
    title = {Estimating the annual volume of hematologic cancer cases per hematologist{\textendash}oncologist in the United States: are we treating rare cancers too rarely?},
    author = {Aishwarya Ravindran and Wilson I. Gonsalves and Shahrukh K. Hashmi and Prashant Kapoor and Ariela L. Marshall and Mustaqeem A. Siddiqui and Ronald S. Go},
    journal = {Leukemia {\&}amp$\mathsemicolon$ Lymphoma},
    number = {1},
    publisher = {Informa {UK} Limited},
}

@article{RayCoquard2017,
    title = {Improving treatment results with reference centres for~rare cancers: where do we stand?},
    author = {Isabelle Ray-Coquard and Eric Pujade Lauraine and Axel Le Cesne and Patricia Pautier and Marie Cecile Vacher Lavenue and Annalisa Trama and Paolo Casali and Jean Michel Coindre and Jean Yves Blay},
    journal = {European Journal of Cancer},
    month = {may},
    publisher = {Elsevier {BV}},
    year = {2017},
    volume = {77},
    doi = {10.1016/j.ejca.2017.02.006},
    relevance = {relevant},
    pages = {90--98},
}

@article{Reguerre2010,
    volume = {97},
    author = {Y. R{\'{e}}guerre and B. Lacour and N. Andr{\'{e}} and L. Claude and F. Hameury and F. Lavrand and N. Kalfa and M. Peuchmaur and D. Orbach},
    month = {sep},
    publisher = {Elsevier {BV}},
    number = {9},
    doi = {10.1684/bdc.2010.1169},
    journal = {Bulletin du Cancer},
    title = {Tumeurs rares en p{\'{e}}diatrie : particularit{\'{e}}s {\'{e}}pid{\'{e}}miologiques et organisation de leur prise en charge dans le cadre de la Soci{\'{e}}t{\'{e}} fran{\c{c}}aise des cancers et des leuc{\'{e}}mies de l{\textquotesingle}enfant et de l{\textquotesingle}adolescent ({SFCE})},
    year = {2010},
    pages = {1041--1045},
}

@article{Reinke2021,
    title = {Meaningful engagement of the patient in rare cancer research: sarcoma as an exemplar},
    number = {4},
    month = {aug},
    volume = {45},
    pages = {100772},
    year = {2021},
    journal = {Current Problems in Cancer},
    author = {Denise K. Reinke},
    doi = {10.1016/j.currproblcancer.2021.100772},
    publisher = {Elsevier {BV}},
}

@article{Richter2015,
    author = {Trevor Richter and Sandra Nestler-Parr and Robert Babela and Zeba M. Khan and Theresa Tesoro and Elizabeth Molsen and Dyfrig A. Hughes},
    journal = {Value in Health},
    month = {sep},
    number = {6},
    pages = {906--914},
    publisher = {Elsevier {BV}},
    year = {2015},
    doi = {10.1016/j.jval.2015.05.008},
    title = {Rare Disease Terminology and Definitions{\textemdash}A Systematic Global Review: Report of the {ISPOR} Rare Disease Special Interest Group},
    volume = {18},
}

@article{RodriguezMartin2018,
    pages = {1--10},
    year = {2018},
    journal = {Journal of Cancer Policy},
    month = {dec},
    doi = {10.1016/j.jcpo.2018.08.001},
    date = {2018-12},
    issn = {22135383},
    langid = {english},
    shortjournal = {Journal of Cancer Policy},
    journaltitle = {Journal of Cancer Policy},
    qualityassured = {qualityAssured},
    title = {Cost-effectiveness of healthcare interventions for rare cancers: Evidence from a systematic literature review and meta-analysis},
    urldate = {2022-05-17},
    file = {Accepted Version:C\:\\Users\\Kostadin\\Zotero\\storage\\9XNQ8AVQ\\Rodriguez-Martin и др. - 2018 - Cost-effectiveness of healthcare interventions for.pdf:application/pdf},
    shorttitle = {Cost-effectiveness of healthcare interventions for rare cancers},
    publisher = {Elsevier {BV}},
    author = {Rodriguez-Martin, Ana-Maria and Zacharopoulou, Panagiota and Hassan, A. Bassim and Tsiachristas, Apostolos},
    url = {https://linkinghub.elsevier.com/retrieve/pii/S2213538318300146},
    volume = {18},
}

@article{Rosell2019,
    title = {Function, information, and contributions: An evaluation of national multidisciplinary team meetings for rare cancers},
    author = {Linn Rosell and Jessica Wihl and Oskar Hagberg and Björn Ohlsson and Mef Nilbert},
    month = {jan},
    pages = {203636131984169},
    doi = {10.1177/2036361319841696},
    volume = {11},
    year = {2019},
    journal = {Rare Tumors},
    publisher = {{SAGE} Publications},
}

@article{Saddoughi2016,
    year = {2016},
    publisher = {Elsevier {BV}},
    title = {Surgical Resection of Rare Esophageal Cancers},
    volume = {101},
    journal = {The Annals of Thoracic Surgery},
    month = {jan},
    number = {1},
    pages = {311--315},
    doi = {10.1016/j.athoracsur.2015.06.015},
    author = {Sahar A. Saddoughi and Jim Taswell and William S. Harmsen and Matthew L. Inra and Shanda H. Blackmon and Francis C. Nichols and Stephen D. Cassivi and Dennis A. Wigle and K. Robert Shen and Mark S. Allen},
}

@article{Salmeron2021,
    month = {oct},
    file = {:Salmeron2021 - Estimating Country Specific Incidence Rates of Rare Cancers_ Comparative Performance Analysis of Modeling Approaches Using European Cancer Registry Data.pdf:PDF},
    number = {3},
    readstatus = {read},
    year = {2021},
    doi = {10.1093/aje/kwab262},
    author = {Diego Salmer{\'{o}}n and Laura Botta and Jos{\'{e}} Miguel Mart{\'{\i}}nez and Annalisa Trama and Gemma Gatta and Josep M Borr{\`{a}}s and Riccardo Capocaccia and Ramon Cl{\`{e}}ries and},
    journal = {American Journal of Epidemiology},
    pages = {487--498},
    title = {Estimating Country-Specific Incidence Rates of Rare Cancers: Comparative Performance Analysis of Modeling Approaches Using European Cancer Registry Data},
    volume = {191},
    publisher = {Oxford University Press ({OUP})},
}

@article{Sandler2021,
    title = {Editorial: Special issue on rare cancers},
    number = {4},
    journal = {Current Problems in Cancer},
    year = {2021},
    volume = {45},
    pages = {100774},
    publisher = {Elsevier {BV}},
    readstatus = {read},
    month = {aug},
    doi = {10.1016/j.currproblcancer.2021.100774},
    author = {Abby Sandler and Karlyne Reilly and Brigitte Widemann},
}

@article{Sandrucci2015,
    author = {S. Sandrucci and G. Gatta and A. Trama and A.P. Dei Tos and P.G. Casali},
    month = {sep},
    number = {9},
    pages = {1115--1117},
    title = {Specialized teams or specialist networks for rare cancers?},
    publisher = {Elsevier {BV}},
    volume = {41},
    year = {2015},
    journal = {European Journal of Surgical Oncology ({EJSO})},
    doi = {10.1016/j.ejso.2015.04.002},
}

@article{Sandrucci2019,
    author = {Sergio Sandrucci and Gemma Gatta},
    journal = {European Journal of Surgical Oncology},
    pages = {1--2},
    year = {2019},
    month = {jan},
    publisher = {Elsevier {BV}},
    volume = {45},
    doi = {10.1016/j.ejso.2018.06.028},
    number = {1},
    title = {Rare cancers: A network for better care},
}

@article{Sandrucci2019a,
    doi = {10.1016/j.ejso.2017.12.012},
    month = {jan},
    title = {Centers of excellence or excellence networks: The surgical challenge and quality issues in rare cancers},
    volume = {45},
    pages = {19--21},
    publisher = {Elsevier {BV}},
    year = {2019},
    journal = {European Journal of Surgical Oncology},
    number = {1},
    author = {S. Sandrucci and P. Naredi and S. Bonvalot},
}

@article{Satake2022,
    volume = {33},
    author = {Tomoyuki Satake and Chigusa Morizane and Ryoko Rikitake and Shintaro Iwata and Hidekazu Hirano and Dai Ogata and Tatsunori Shimoi and Kazuki Sudo and Seiichi Yoshimoto and Naoya Yamazaki and Yoko Katoh and Takahiro Higashi and Akira Kawai},
    year = {2022},
    doi = {10.1016/j.annonc.2022.05.038},
    pages = {S473--S474},
    month = {jul},
    publisher = {Elsevier {BV}},
    readstatus = {skimmed},
    journal = {Annals of Oncology},
    title = {O12-2 The epidemiology of rare cancers from National Cancer Registry in Japan},
}

@article{Schneider2010,
    author = {D. T. Schneider and I. B. Brecht},
    publisher = {Georg Thieme Verlag {KG}},
    month = {may},
    doi = {10.1055/s-0030-1252028},
    journal = {Klinische Pädiatrie},
    title = {Care for Rare Cancers: Improved Care Requires Improved Communication},
    volume = {222},
    year = {2010},
    pages = {124--126},
    number = {03},
}

@article{Schwarze2020,
    author = {Katharina Schwarze and James Buchanan and Jilles M. Fermont and Helene Dreau and Mark W. Tilley and John M. Taylor and Pavlos Antoniou and Samantha J.L. Knight and Carme Camps and Melissa M. Pentony and Erika M. Kvikstad and Steve Harris and Niko Popitsch and Alistair T. Pagnamenta and Anna Schuh and Jenny C. Taylor and Sarah Wordsworth},
    title = {The complete costs of genome sequencing: a microcosting study in cancer and rare diseases from a single center in the United Kingdom},
    year = {2020},
    month = {jan},
    doi = {10.1038/s41436-019-0618-7},
    number = {1},
    journal = {Genetics in Medicine},
    volume = {22},
    publisher = {Elsevier {BV}},
    pages = {85--94},
}

@article{Shah2021,
    publisher = {Elsevier {BV}},
    author = {Harsh Shah and Amre Ghazzal and Dweep Barbhaya and William Weigold},
    journal = {Journal of the American College of Cardiology},
    title = {{RECURRENT} {PERICARDIAL} {EFFUSION}: {AN} {EARLY} {PRESENTATION} {OF} A {RARE} {CANCER}},
    volume = {77},
    doi = {10.1016/s0735-1097(21)04321-7},
    year = {2021},
    month = {may},
    number = {18},
    pages = {2966},
}

@article{Sharifnia2017,
    title = {Emerging Opportunities for Target Discovery in Rare Cancers},
    year = {2017},
    pages = {1075--1091},
    journal = {Cell Chemical Biology},
    month = {sep},
    relevance = {relevant},
    volume = {24},
    publisher = {Elsevier {BV}},
    number = {9},
    author = {Tanaz Sharifnia and Andrew L. Hong and Corrie A. Painter and Jesse S. Boehm},
    doi = {10.1016/j.chembiol.2017.08.002},
}

@article{Shimoi2016,
    journal = {Annals of Oncology},
    doi = {10.1093/annonc/mdw489},
    month = {nov},
    year = {2016},
    volume = {27},
    publisher = {Elsevier {BV}},
    pages = {vii44},
    title = {Rare cancers$\mathsemicolon$ off label use},
    author = {Tatsunori Shimoi and Kan Yonemori and Akira Kawai},
}

@article{Shin2015,
    number = {4},
    title = {Oncologist Perspectives on Rare Cancer Care: A Nationwide Survey},
    doi = {10.4143/crt.2014.086},
    author = {Dong Wook Shin and Juhee Cho and Hyung Kook Yang and So Young Kim and Su Hyun Lee and Beomseok Suh and Hee-Young Shin and Hyun Joo Lee and Dae Ghon Kim and Jong Hyock Park},
    publisher = {Korean Cancer Association},
    journal = {Cancer Research and Treatment},
    pages = {591--599},
    volume = {47},
    year = {2015},
    month = {jan},
}

@article{shrivastava_cancer_2017,
    number = {2},
    qualityassured = {qualityAssured},
    doi = {10.4103/jrcr.jrcr_26_17},
    urldate = {2022-05-17},
    issn = {0973-0168},
    shorttitle = {Cancer research},
    pages = {91},
    url = {http://www.journalrcr.org/text.asp?2017/8/2/91/208031},
    title = {Cancer research: Challenges and promise for individualized treatment},
    langid = {english},
    journaltitle = {Journal of Radiation and Cancer Research},
    shortjournal = {J Radiat Cancer Res},
    author = {Shrivastava, {ShyamKishore}},
    date = {2017},
    volume = {8},
}

@article{Sidiropoulos2012,
    title = {Real time decision support system for diagnosis of rare cancers, trained in parallel, on a graphics processing unit},
    author = {Konstantinos Sidiropoulos and Dimitrios Glotsos and Spiros Kostopoulos and Panagiota Ravazoula and Ioannis Kalatzis and Dionisis Cavouras and John Stonham},
    journal = {Computers in Biology and Medicine},
    doi = {10.1016/j.compbiomed.2011.12.004},
    month = {apr},
    publisher = {Elsevier {BV}},
    pages = {376--386},
    number = {4},
    volume = {42},
    year = {2012},
}

@article{Siesling2012,
    year = {2012},
    journal = {European Journal of Cancer},
    doi = {10.1016/j.ejca.2012.02.047},
    pages = {949--960},
    month = {may},
    publisher = {Elsevier {BV}},
    number = {7},
    author = {Sabine Siesling and Jan Maarten van der Zwan and Isabel Izarzugaza and Jana Jaal and Tom Treasure and Roberto Foschi and Umberto Ricardi and Harry Groen and Andrea Tavilla and Eva Ardanaz},
    volume = {48},
    title = {Rare thoracic cancers, including peritoneum mesothelioma},
}

@article{Sklan2014,
    month = {nov},
    volume = {15},
    author = {Alexandra Sklan},
    number = {12},
    title = {Inadequate funding for rare cancers in Australia},
    publisher = {Elsevier {BV}},
    journal = {The Lancet Oncology},
    doi = {10.1016/s1470-2045(14)70497-8},
    pages = {e534},
    year = {2014},
}

@article{Sledge2005,
    year = {2005},
    pages = {1614--1615},
    number = {8},
    publisher = {American Society of Clinical Oncology ({ASCO})},
    readstatus = {read},
    month = {mar},
    doi = {10.1200/jco.2005.01.016},
    author = {George W. Sledge},
    ranking = {rank4},
    volume = {23},
    journal = {Journal of Clinical Oncology},
    title = {What Is Targeted Therapy?},
}

@article{sokolowski_proof--concept_2014,
    langid = {english},
    title = {Proof-of-concept rare cancers in drug development: the case for rhabdomyosarcoma},
    url = {https://www.nature.com/articles/onc2013129},
    doi = {10.1038/onc.2013.129},
    journaltitle = {Oncogene},
    pages = {1877--1889},
    author = {Sokolowski, E and Turina, C B and Kikuchi, K and Langenau, D M and Keller, C},
    number = {15},
    issn = {0950-9232, 1476-5594},
    urldate = {2022-05-17},
    shorttitle = {Proof-of-concept rare cancers in drug development},
    date = {2014-04-10},
    volume = {33},
    shortjournal = {Oncogene},
    qualityassured = {qualityAssured},
}

@article{Srinivas2021,
    month = {apr},
    author = {Sujay Srinivas and Jyoti Bajpai},
    journal = {Journal of Immunotherapy and Precision Oncology},
    year = {2021},
    volume = {4},
    title = {Checkpoint Inhibitors in Checkmating Rare Cancers},
    doi = {10.36401/jipo-20-x10},
    publisher = {Innovative Healthcare Institute},
    number = {4},
    pages = {178--179},
}

@article{Stacchiotti2012,
    journal = {Annals of Oncology},
    month = {feb},
    doi = {10.1093/annonc/mdr066},
    title = {Gemcitabine in advanced angiosarcoma: a retrospective case series analysis from the Italian Rare Cancer Network},
    pages = {501--508},
    number = {2},
    publisher = {Elsevier {BV}},
    author = {S. Stacchiotti and E. Palassini and R. Sanfilippo and B. Vincenzi and M.G. Arena and A.M. Bochicchio and P. De Rosa and A. Nuzzo and S. Turano and C. Morosi and A.P. Dei Tos and S. Pilotti and P.G. Casali},
    volume = {23},
    year = {2012},
}

@article{Stiller2013,
    doi = {10.1016/j.ejca.2012.09.011},
    volume = {49},
    pages = {684--695},
    publisher = {Elsevier {BV}},
    journal = {European Journal of Cancer},
    author = {C.A. Stiller and A. Trama and D. Serraino and S. Rossi and C. Navarro and M.D. Chirlaque and P.G. Casali},
    month = {feb},
    title = {Descriptive epidemiology of sarcomas in Europe: Report from the {RARECARE} project},
    year = {2013},
    number = {3},
}

@article{tamaki_burden_2014,
    journaltitle = {Cancer Epidemiology},
    urldate = {2022-05-17},
    langid = {english},
    author = {Tamaki, Tomoko and Dong, Yiqi and Ohno, Yuko and Sobue, Tomotaka and Nishimoto, Hiroshi and Shibata, Akiko},
    qualityassured = {qualityAssured},
    date = {2014-10},
    shorttitle = {The burden of rare cancer in Japan},
    shortjournal = {Cancer Epidemiology},
    pages = {490--495},
    url = {https://linkinghub.elsevier.com/retrieve/pii/S1877782114001404},
    title = {The burden of rare cancer in Japan: Application of the {RARECARE} definition},
    volume = {38},
    doi = {10.1016/j.canep.2014.07.014},
    issn = {18777821},
    number = {5},
}

@article{Tan2003,
    relevance = {relevant},
    title = {Strategy for randomised clinical trials in rare cancers},
    journal = {{BMJ}},
    doi = {10.1136/bmj.327.7405.47},
    volume = {327},
    number = {7405},
    author = {S.-B. Tan},
    month = {jul},
    readstatus = {read},
    year = {2003},
    pages = {47--49},
    publisher = {{BMJ}},
}

@article{tawbi2017pembrolizumab,
    volume = {18},
    author = {Tawbi, Hussein A and Burgess, Melissa and Bolejack, Vanessa and Van Tine, Brian A and Schuetze, Scott M and Hu, James and D'Angelo, Sandra and Attia, Steven and Riedel, Richard F and Priebat, Dennis A and others},
    readstatus = {read},
    year = {2017},
    number = {11},
    publisher = {Elsevier},
    doi = {10.1016/S1470-2045(17)30624-1},
    journal = {The Lancet Oncology},
    pages = {1493--1501},
    title = {Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial},
}

@article{Thatcher2005,
    title = {Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)},
    doi = {10.1016/s0140-6736(05)67625-8},
    number = {9496},
    volume = {366},
    month = {oct},
    year = {2005},
    publisher = {Elsevier {BV}},
    pages = {1527--1537},
    author = {Nick Thatcher and Alex Chang and Purvish Parikh and Jos{\'{e}} Rodrigues Pereira and Tudor Ciuleanu and Joachim von Pawel and Sumitra Thongprasert and Eng Huat Tan and Kristine Pemberton and Venice Archer and Kevin Carroll},
    journal = {The Lancet},
}

@article{the_lancet_oncology_very_2001,
    author = {The Lancet Oncology},
    langid = {english},
    urldate = {2022-05-17},
    pages = {189},
    issn = {14702045},
    readstatus = {read},
    doi = {10.1016/S1470-2045(00)00273-4},
    title = {Very rare cancers — a problem neglected},
    shortjournal = {The Lancet Oncology},
    journaltitle = {The Lancet Oncology},
    qualityassured = {qualityAssured},
    volume = {2},
    url = {https://linkinghub.elsevier.com/retrieve/pii/S1470204500002734},
    number = {4},
    date = {2001-04},
}

@article{Trama2012,
    publisher = {Il Pensiero Scientifico Editore},
    doi = {10.1700/1190.13194},
    pages = {550-8},
    title = {The burden of rare cancers in Italy: the surveillance of rare cancers in Italy (RITA) project.},
    volume = {98 5},
    year = {2012},
    author = {Annalisa Trama and Sandra Mallone and Stefano Ferretti and Francesca Meduri and Riccardo Capocaccia and Gemma Gatta},
    journal = {Tumori},
}

@article{Trama2016,
    pages = {22--32},
    doi = {10.5301/tj.5000559},
    publisher = {{SAGE} Publications},
    journal = {Tumori Journal},
    number = {1},
    volume = {103},
    month = {mar},
    title = {Data Quality in Rare Cancers Registration: The Report of the {RARECARE} Data Quality Study},
    year = {2016},
    author = {Annalisa Trama and Rafael Marcos-Gragera and Maria Jos{\`{e}} S{\'{a}}nchez P{\'{e}}rez and Jan Maarten van der Zwan and Eva Ardanaz and Christine Bouchardy and Juan Manuel Melchor and Carmen Martinez and Riccardo Capocaccia and Massimo Vicentini and Sabine Siesling and Gemma Gatta and},
}

@article{Tuffaha2018,
    pages = {S110},
    month = {sep},
    volume = {21},
    author = {H Tuffaha and P Scuffham},
    title = {Rare Cancers, no Rare Solutions: Risk Sharing Arrangemnts to Reimburse Medicines for Rare Cancers in Australia},
    publisher = {Elsevier {BV}},
    doi = {10.1016/j.jval.2018.07.839},
    journal = {Value in Health},
    year = {2018},
}

@article{Vinches2019,
    journal = {Annals of Oncology},
    doi = {10.1093/annonc/mdz413.086},
    month = {nov},
    year = {2019},
    pages = {vii24},
    publisher = {Elsevier {BV}},
    author = {M. Vinches and A. Stevovic and I.L. Ray-Coquard and I. Treilleux and P. Meeus and S. Aust and A. Floquet and S. Croce and L. Chalabreysse and N. Girard and J-Y Blay and M. Morfouace},
    title = {Arcagen: An {EORTC}-{SPECTA} project to perform a molecular characterization of rare cancers: Results of the retrospective feasibility cohort},
    volume = {30},
}

@article{Visser2012,
    number = {4},
    author = {O. Visser and J. Adolfsson and S. Rossi and J. Verne and G. Gatta and M. Maffezzini and K.N. Franks},
    doi = {10.1016/j.ejca.2011.10.031},
    volume = {48},
    year = {2012},
    pages = {456--464},
    month = {mar},
    publisher = {Elsevier {BV}},
    journal = {European Journal of Cancer},
    title = {Incidence and survival of rare urogenital cancers in Europe},
}

@article{Vokinger2020,
    author = {K.N. Vokinger and P. Daniore and A.S. Kesselheim},
    doi = {10.1016/j.annonc.2020.08.2307},
    journal = {Annals of Oncology},
    year = {2020},
    volume = {31},
    month = {sep},
    title = {1586MO Pivotal trial endpoints of drugs for rare and non-rare cancers in the {US} and Europe},
    pages = {S1197},
    publisher = {Elsevier {BV}},
}

@article{Walker2020,
    shortjournal = {Cancer Epidemiology},
    publisher = {Elsevier {BV}},
    pages = {101721},
    langid = {english},
    doi = {10.1016/j.canep.2020.101721},
    shorttitle = {Rare cancers in Canada, 2006–2016},
    journaltitle = {Cancer Epidemiology},
    issn = {18777821},
    journal = {Cancer Epidemiology},
    month = {aug},
    date = {2020-08},
    title = {Rare cancers in Canada, 2006–2016: A population-based surveillance report and comparison of different methods for classifying rare cancers},
    urldate = {2022-05-17},
    url = {https://linkinghub.elsevier.com/retrieve/pii/S1877782120300552},
    volume = {67},
    year = {2020},
    qualityassured = {qualityAssured},
    author = {Walker, E.V. and Maplethorpe, E. and Davis, F.G.},
}

@article{Zlatareva201513,
    note = {Cited by: 0},
    url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-84929159214&partnerID=40&md5=a53f2886ae5939d5c587f17fd90dae18},
    year = {2015},
    pages = {13 – 18},
    author = {Zlatareva, Al. and Petrova, G.},
    publication_stage = {Final},
    volume = {17},
    number = {1},
    journal = {General Medicine},
    title = {National health insurance fund cost analysis for rare cancer diseases and orphan drugs},
}

@article{Zwan2013,
    doi = {10.1016/j.ejca.2013.02.029},
    file = {:Zwan2013 - Rare Neuroendocrine Tumours_ Results of the Surveillance of Rare Cancers in Europe Project.pdf:PDF},
    month = {jul},
    number = {11},
    relevance = {relevant},
    volume = {49},
    pages = {2565--2578},
    title = {Rare neuroendocrine tumours: Results of the surveillance of rare cancers in Europe project},
    publisher = {Elsevier {BV}},
    year = {2013},
    journal = {European Journal of Cancer},
    author = {Jan Maarten van der Zwan and Annalisa Trama and Ren{\'{e}}e Otter and Nerea Larra{\~{n}}aga and Andrea Tavilla and Rafael Marcos-Gragera and Angelo Paolo Dei Tos and Eric Baudin and Graeme Poston and Thera Links},
}

@article{Zwan2018,
    number = {4},
    volume = {27},
    journal = {European Journal of Cancer Prevention},
    title = {Rare cancers in The Netherlands: a population-based study},
    month = {jul},
    author = {Jan M. van der Zwan and Boukje A.C. van Dijk and Otto Visser and Han J.H.J.M. van Krieken and Riccardo Capocaccia and Sabine Siesling},
    year = {2018},
    doi = {10.1097/cej.0000000000000166},
    publisher = {Ovid Technologies (Wolters Kluwer Health)},
    pages = {384--390},
}